
==== Front
Int J Mol SciInt J Mol SciijmsInternational Journal of Molecular Sciences1422-0067MDPI 10.3390/ijms20225638ijms-20-05638ReviewThe Novel Perspectives of Adipokines on Brain Health Lee Thomas Ho-yin 1https://orcid.org/0000-0002-7274-0839Cheng Kenneth King-yip 2Hoo Ruby Lai-chong 3Siu Parco Ming-fai 4Yau Suk-yu 1*1 Department of Rehabilitation Sciences, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, 11 Yuk Choi Road, Hung Hum, Hong Kong; thomas.hy.lee@connect.polyu.hk2 Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, 11 Yuk Choi Road, Hung Hom, Hong Kong3 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 11 Sassoon Road, Pokfulam, Hong Kong4 Division of Kinesiology, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 5 Sassoon Road, Pokfulam, Hong Kong* Correspondence: sonata.yau@polyu.edu.hk11 11 2019 11 2019 20 22 563816 10 2019 06 11 2019 © 2019 by the authors.2019Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).First seen as a fat-storage tissue, the adipose tissue is considered as a critical player in the endocrine system. Precisely, adipose tissue can produce an array of bioactive factors, including cytokines, lipids, and extracellular vesicles, which target various systemic organ systems to regulate metabolism, homeostasis, and immune response. The global effects of adipokines on metabolic events are well defined, but their impacts on brain function and pathology remain poorly defined. Receptors of adipokines are widely expressed in the brain. Mounting evidence has shown that leptin and adiponectin can cross the blood–brain barrier, while evidence for newly identified adipokines is limited. Significantly, adipocyte secretion is liable to nutritional and metabolic states, where defective circuitry, impaired neuroplasticity, and elevated neuroinflammation are symptomatic. Essentially, neurotrophic and anti-inflammatory properties of adipokines underlie their neuroprotective roles in neurodegenerative diseases. Besides, adipocyte-secreted lipids in the bloodstream can act endocrine on the distant organs. In this article, we have reviewed five adipokines (leptin, adiponectin, chemerin, apelin, visfatin) and two lipokines (palmitoleic acid and lysophosphatidic acid) on their roles involving in eating behavior, neurotrophic and neuroprotective factors in the brain. Understanding and regulating these adipokines can lead to novel therapeutic strategies to counteract metabolic associated eating disorders and neurodegenerative diseases, thus promote brain health.

adipokineadipose-brain axisbrain healthneurodegenerationdepression
==== Body
1. Introduction
Adipose tissues are recognized as highly dynamic endocrine tissues exhibiting extensive physiological functions [1]. Adipose tissue is composed of mature adipocytes as well as the stromal vascular fraction, where adipose-derived stem cells, blood cells, fibroblasts, and nerves reside [2]. White and brown adipose tissues are the two fat tissues in mammals. The adipocytes in white and brown adipose tissues are morphologically and functionally distinct. Brown adipose tissues are accountable for thermogenesis by their abundant mitochondria and extensive vascularization [3,4], whereas white adipose tissues are preferably responsible for energy storage in the form of triglycerides. During fasting conditions, insulin inhibits lipolysis in white adipose tissues, where triglycerides are hydrolyzed into fatty acids and glycerol to generate energy [5]. In response to the nutritional states, adipose tissue plays an endocrine role by synthesizing and secreting bioactive compounds termed adipokines. Adipokine secretion is essential to energy and metabolic homeostasis [6]. Adipsin and leptin are the first adipokines identified [7,8]. Since then, many pivotal adipokines, such as adiponectin, resistin, and tumor necrosis factor α (TNF-α), have been extensively studied in metabolism and metabolic syndromes [9]. Novel adipokines, including chemerin, omentin, apelin, and adipocyte fatty acid-binding protein, have been identified by their metabolic functions resembling former adipokines and their alterations afflicted by metabolic diseases in humans [10].

The adipose-brain axis was first established with the discovery of leptin as an endocrine hormone targeting the hypothalamus to regulate energy balance, satiety, metabolism, and body weight [11]. It was later demonstrated that leptin signaling is also involved in hippocampal neuroplasticity [12]. De la Monte et al. have suggested that energy metabolism, glucose utilization, and insulin sensitization are compromised in Alzheimer’s disease (AD) patients, whereas these pathological symptoms may contribute to AD neuropathology [13,14,15,16]. Since AD neuropathology highly resembles the pathology of diabetes mellitus, AD is now recognized as the ‘type 3 diabetes’. Adiponectin promotes insulin sensitivity [17], whereas adiponectin deficiency exacerbates insulin resistance [18] and AD neuropathology [19]. Concerns are raised regarding how metabolic syndromes are linked to neurodegenerative diseases and mood disorders [20,21]. Given that adipose tissue is a major organ to regulate metabolism through adipokines, understanding the central function of adipokines in the brain can illustrate how the adipose-brain crosstalk works to prevent metabolic diseases and to promote brain health.

Metabolic dysfunction could share common molecular mechanisms with neurodegenerative diseases [22]. Therefore, emerging studies aim at investigating how adipose tissue exerts neuroprotective effects and influences neuroplasticity through secreting adipokines. Notably, several adipokines can cross the blood–brain barrier and act on the brain directly [1], while a damaged barrier will hinder adipose-secreting compounds entering the brain [23]. At present, it is noticeable that adipokines can modulate neuroplasticity. Accumulated studies have shown that leptin and adiponectin pathways can regulate cell proliferation [24,25], survival [19,26,27], and synaptic plasticity [12,28] by modulating cellular metabolism [29,30] and suppressing inflammatory response [31,32,33] in the brain. Previous studies focus on the acute action of leptin on synaptic plasticity, whereas recent studies report insulin resistance afflicts circulating leptin levels and affects central neuroplasticity and cognitive functions. Besides, animal studies have demonstrated a possible link between metabolic disorders with aberrant circulating adipokine levels and cognitive behavioral deficits [34,35,36,37,38] or neuropathology [39,40,41].

This review summarizes the emerging evidence on the roles of five adipokines, including leptin, adiponectin, chemerin, apelin, and visfatin, on promoting neuroplasticity. Furthermore, this review will discuss how diet-, obesity-, and diabetes-related conditions alter the adipokine levels and impair neuroplasticity and cognitive function in terms of mood as well as learning and memory.

2. Effects of Conventional and Novel Adipokines on the Brain
The neuroendocrine roles of leptin and adiponectin have been widely studied. Leptin and adiponectin receptors are widely expressed across many brain regions, in particular, the hippocampus, a critical region for spatial learning and memory formation, and emotional regulation [42]. Both leptin and adiponectin are shown to affect synaptic plasticity in the hippocampus. However, the neuroprotective effects of other adipokines, including chemerin, apelin, and visfatin, are mostly unknown.

2.1. Leptin
Leptin is mostly secreted by white adipose tissue to regulate energy homeostasis by suppressing food intake and thereby reducing weight loss [43]. Circulating leptin levels are positively correlated with adiposity [44] and caloric intake [45,46,47,48,49]. In the obese population, increased adiposity is the primary cause of hyperleptinemia, a condition with high circulating leptin levels [44]. Obese subjects are refractory to the anorexigenic effect of leptin due to leptin resistance in the brain and peripheral tissues [50]. Similarly, patients with type 2 diabetes mellitus comorbid with obesity show both insulin-resistance and hyperleptinemia [51]. Multiple studies have demonstrated the effectiveness of exogenous leptin administration on improving insulin resistance in different obese and diabetic rodent models. Mouse models that feature obesity, hyperglycemia, hyperinsulinemia, particularly db/db (leptin-deficient) mice, and Zucker fa/fa (loss-of-function leptin receptor) rats resemble type 2 diabetic conditions in humans. Infusion of recombinant leptin for seven days is sufficient to ameliorate hyperglycemia and hyperinsulinemia in leptin-deficient ob/ob mice [52]. Leptin treatment can also improve insulin resistance, and glucose and lipid imbalances in some type 2 diabetic models [53,54,55,56]. However, mice receiving chronic (>20 weeks) high-fat diet are resistant to leptin even when leptin is directly infused into the cerebral ventricle of the brain [57,58,59,60]. Prominently, leptin also fails to improve diabetes and insulin resistance in type 2 diabetic patients comorbid with obesity [61,62]. These suggest that leptin replacement therapy is feasible when deficient. However, further elevation in the leptin-resistant state will not improve metabolic syndrome.

Adiposity hinges on excessive caloric intake and accumulation, whereas food consumption is a complex behavior integrating energy homeostasis, reward system, and stress. Leptin is an appetite hormone, where leptin receptors are expressed in multiple brain regions [63]. Leptin exerts dual actions to regulate anorexigenic-mediated energy homeostasis [64] as well as to suppress the food-cued reward circuit in the hypothalamus [65,66]. Hypothalamus is the main target of leptin in the brain by eliciting a homeostatic response to energy accumulation in accord with nutritional states. In response to energy accumulation, leptin inhibits orexigenic neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) as well as activates the anorexigenic proopiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus (ARC). The inclusive anorexigenic effect prevails during energy accumulation after feeding together with an increased body fat oxidation, and hence suppresses leptin synthesis and secretion in a negative feedback loop [67]. On the other hand, plasma leptin levels are decreased by fasting before fat depletion [68], which in turn, disinhibits orexigenic action and stimulates the appetite.

Hedonic behavior in response to food is mediated by the mesolimbic circuit involving endocannabinoid [69], orexinergic [70], and dopaminergic signaling. The food-induced hedonic circuit can possibly override homeostatic feeding. The lateral hypothalamic (LH) together with the mesolimbic reward circuit, which involves the ventral tegmental area (VTA) and nucleus accumbens (NAc) predominate the hedonic circuit, where leptin elicits anorectic action by inhibiting multiple signaling along the circuit [71,72,73]. Orexin is a neuropeptide that mediates energy sensing, appetite, body weight, and reinforces reward behaviors [74,75,76]. Orexin-expressing neurons located in the LH innervate in the VTA, where leptin receptors are expressed [77]. Leptin can suppress activities of orexin-expressing neurons in the LH, as shown in electrophysiological recordings [77]. Besides, intra-LH leptin infusion abolishes high-fat diet-conditioned place preference mediated by orexin-expressing neurons [77]. Of note, endocannabinoid signaling is in part involved in the leptin inhibitory action on orexin-expressing neurons. Leptin deficiency and high-fat diet could enhance cannabinoid receptor-mediated presynaptic inhibitory control of orexin-expressing neurons in the hypothalamic ARC [69]. These findings taken together suggest the leptin suppresses hedonic behavior in the hypothalamus involving orexigenic and endocannabinoid signaling. In addition, dopamine release in the NAc is an adaptive response to palatable food consumption in association with reward learning and incentive salience [78,79,80]. A recent review has comprehensively addressed the crosstalk of leptin and dopamine signaling in inhibiting the food reward system through the LH-VTA-NAc neural circuit [81]. The LH GABA-ergic projection to the VTA expresses leptin receptors [82]. Leptin promotes GABA release from the LH to VTA is associated with reduced food consumption in leptin-deficient mice [82]. The inhibitory effect of leptin in the reward circuit is further supported by the lentiviral-mediated knockdown of the leptin receptor in the LH [83]. Finally, leptin receptors are also expressed in dopaminergic innervation from the VTA to the NAc. Intra-VTA infusion of leptin suppresses food intake [84]. Inhibition of dopaminergic neuron activity in the VTA neurons [85] and the reduced dopamine levels in the NAc [86] may downregulate the reward system. The underlying molecular signaling for leptin inhibition in the VTA dopaminergic neuron may activate the Janus kinase-signal transducer and activator of transcription proteins JAK/STAT/PI3K/mTOR pathway [84,87]. Significantly, long-term overexpression of leptin in the VTA causes leptin receptor desensitization [88]. Conversely, adenoviral-mediated knockdown of leptin receptor in the VTA promotes food intake and sucrose preference [89], and leptin antagonism or knockout in the VTA increases NAc dopamine levels [90]. The abovementioned studies concertedly suggest the overconsumption behavior and continuous body weight gain regardless of hyperleptinemia in obese subjects [91]. Enlarged adipocyte is the culprit of hyperleptinemia. And potentially, instead of exhibiting a stronger anorexigenic effect or a stronger inhibition of hedonic reward, prolonged hyperleptinemia may desensitize the leptin receptor-mediated signaling [60]. These result in a vicious cycle of hedonic eating and obesity.

Excessive caloric intake and energy accumulation are not the only causes of obesity. Chronic atypical antipsychotic medication is obesogenic in association with severe metabolic disorders, including hyperglycemia, insulin resistance, and hyperleptinemia [92,93,94,95,96,97,98]. In particular, weight gain, increased food consumption, and hyperleptinemia are frequently reported in psychotic patients receiving olanzapine medication [99,100]. Significant elevation of circulating leptin is detected in schizophrenic subjects receiving haloperidol medication (pre, typical antipsychotic treatment) versus risperidone and clozapine medication (post, atypical antipsychotic treatment) [101]. Elevated leptin levels and weight gain in schizophrenic patients treated with atypical antipsychotics may be involved in an adiposity-induced feedback mechanism [102]. Rodent studies further support the fact that the atypical antipsychotics, namely risperidone and olanzapine, are obesogenic as well as induce leptin expression and secretion [103,104,105,106]. Essentially, antipsychotics can act on multiple neuroendocrine pathways. Alongside with serotoninergic antagonism that may underline hedonic feeding behaviors and atypical weight gain [107,108,109], some atypical antipsychotics can contravene energy homeostasis by inhibiting peripheral adrenergic system [97]. β-3 antagonism by atypical antipsychotics can not only disrupt energy homeostasis [110,111] but also induce hyperleptinemia [112]. In sum, atypical antipsychotics are obesogenic by contravening brain anorexigenic and reward circuit as well as disrupting normal adipocyte functioning.

Besides, leptin receptors are found in the hippocampus and neocortex, suggesting their possible roles in the cognitive process [63]. Leptin resistance in obese and diabetic patients can be linked to impaired leptin receptor signaling [64] and leptin insensitivity at the blood–brain barrier [50,113]. Although both leptin mRNA and protein expressions are widely detected in the brain [114,115], circulating leptin can pass through the blood–brain barrier [116] and could function as a neurotrophic factor in modulating neuroplasticity and cognitive functions [117]. db/db mice, which show loss of function in leptin receptor signaling, display neuronal atrophy in the hippocampus, including reduced hippocampal progenitor cell proliferation [118], reduced dendritic branching and dendritic spine [119]. Besides, both db/db mice and Zucker fa/fa rats show spatial memory deficits in the Morris water maze task [118,120,121] and exhibit despair behaviors [122], suggesting that impaired leptin signaling could affect structural plasticity in the hippocampus. HFD-induced diabetic model [123] and db/db mice [124] display hyperleptinemia and leptin resistance. Enhancing leptin levels enhances neuroplasticity and cognitive function in rodents under physiological conditions. For example, intraperitoneal injection with 1 mg/kg recombinant leptin continuously for 14 days promotes hippocampal cell proliferation and survival of newborn neurons in healthy male mice [24]. An in vitro study has demonstrated that leptin promotes dendritic branching and spine maturation in cultured primary neurons [125]. Moreover, leptin elicits a rapid antidepressant effect by reducing depression-like behavior in the forced swim test and tail suspension test [126]. Intrahippocampal infusion with leptin immediately after training improves memory processing in T-maze footshock avoidance and step down passive avoidance tests [127], suggesting that leptin has a direct effect on influencing hippocampal function and enhances behavioral outcome. Notably, previous studies have shown that leptin treatment via systemic injection or intra-hippocampus injection to the dorsal part can improve spatial and context-cued learning and memory. Nonetheless, a study has reported that leptin infusion in the ventral hippocampus, but not in the dorsal hippocampus, impairs memory consolidation for the spatial location of food [128]. A recent review suggests that activating the leptin signaling pathway, specifically in the ventral hippocampus, could suppress spatial working memory [129]. Mechanisms of how leptin affects structural plasticity in the hippocampus are still unclear. Leptin receptors are coupled to JAK/STAT and PI3K/Akt signaling cascades in hippocampal neurons. Activation of the above cascades increases the production of manganese superoxide dismutase (Mn-SOD), an antioxidant enzyme, as well as the anti-apoptotic protein Bcl-xL. The synergistic antioxidant and anti-apoptotic effects may stabilize the mitochondrial membrane potential, and hence lessen mitochondrial oxidative stress to promote neuronal proliferation in the hippocampus [26]. Leptin treatment could increase hippocampal cell proliferation and survival by increasing mitochondrial functioning. In addition, leptin can also promote synaptogenesis via increasing expression of microRNA-132 (miR-132) [119]. Leptin induces long-term potentiation (LTP) by modulating post-synaptic signaling pathway and glutamatergic N-methyl-D-aspartate (NMDA) receptor. LTP is considered as a cellular mechanism of learning and memory formation. The NMDA receptor-dependent LTP in the CA1 region of the hippocampus underlies spatial memory formation [130]. Both db/db mice and Zucker fa/fa rats with defective leptin receptors impair hippocampal LTP formation [120], whereas infusion of 1 µM leptin into the hippocampal dentate gyrus enhances LTP [131]. Ex vivo studies also show that leptin can increase pharmacologically-isolated NMDA receptor-mediated excitatory postsynaptic currents (EPSCs) in the CA1 region in acute rat hippocampal slices [132] (Table 1).

Neuroprotective effects of leptin have also been shown in animal models. Eight weeks of systemic infusion with leptin reduces amyloid-β levels in the brain and serum of six-month old CRND8 transgenic mouse model of AD. Leptin treatment also improves object recognition and contextual fear learning [133]. Moreover, intracerebroventricular injection of leptin (1 µg) for ten days improves spatial memory in Y-maze and water maze tasks, as well as restores LTP in the CA1 region in an Aβ-induced AD rat model [134]. The neuroprotective effects of leptin could be linked to a leptin/JAK2/STAT3 signaling pathway [135] or leptin mediated PI3K/Akt/mTOR signaling pathway [136]. In sum, leptin can directly modulate structural and synaptic plasticity, however prolonged elevation in leptin levels could be detrimental to neuroplasticity under hyperleptinemia condition.

2.2. Adiponectin
Adiponectin is secreted by white adipose tissue and exerts anti-inflammatory effects on both endocrine and cardiovascular systems [137,138]. Adiponectin receptors (AdipoRs) express differentially in peripheral tissues. AdipoR1 is highly expressed in skeletal muscle, while AdipoR2 is abundant in the liver [139]. Hypoadiponectinemia, a condition of low circulating adiponectin, is commonly observed in obese and type 2 diabetic patients [140,141,142]. In line with clinical evidence, diabetic and obese mice also have reduced adiponectin expression in adipose tissues as well as the blood [143,144,145,146]. Circulating adiponectin levels are reduced in obesity [140,141,142], whereas the expressions of adiponectin receptors are increased, as evidenced by higher mRNA expressions of AdipoR1 in skeletal muscle in obese subjects [147] and AdipoR2 in insulin-resistant subjects [148]. Recombinant adiponectin treatment can reduce body weight and increase hepatic and muscular insulin sensitivity in an adiponectin-deficient mouse model [149]. Similarly, patients receiving rosiglitazone, an insulin sensitizer targeting the adipose tissue, experience increased plasma adiponectin by approximately two-fold [150]. These findings indicate that upregulating adiponectin expression can improve insulin sensitivity. Adiponectin receptors (AdipoR) are widely expressed in rodent brains, including the hypothalamus, brainstem, prefrontal cortex, and hippocampus, suggesting its role in the CNS in addition to its role in metabolism [27,139,151,152,153,154,155,156,157,158,159]. Overnight fasting by food deprivation for sixteen hours concomitantly downregulates mRNA expression of adiponectin and upregulates mRNA expression levels of AdipoR1 and APPL1 in the hypothalamic ARC [160], a brain area in the mediobasal hypothalamus regulating energy and glucose homeostasis [161].

Adiponectin could enter the blood–brain barrier since the low-molecular weight trimeric form of adiponectin is detectable in cerebrospinal fluid after intravenous injection in adiponectin-deficient mice [25,162]. Prominently, adiponectin is involved in energy homeostasis and appetite in concordance with leptin. A recent investigation shows that adiponectin promotes anorexigenic POMC activity in the hypothalamic ARC [163] possibly through PI3-K signaling [164]. Adiponectin elicits an excitatory effect on POMC neurons in a leptin-receptor dependent manner [163], whereas leptin synergistically potentiates adiponectin excitatory effect on POMC neuronal activity [163]. Simultaneously, adiponectin inhibits the neighboring orexigenic NPY/AgRP neurons, which then disinhibit POMC activity [163]. Further studies show that adiponectin action on the hypothalamic POMC activity may occur in a glucose-dependent reciprocal manner. Adiponectin infusion in the cerebral ventricle exerts an orexigenic effect at high glucose levels but is anorexigenic at low glucose levels [165]. Moreover, adiponectin increases the anorexigenic POMC activity at low glucose levels (2.5–5 mM), mimicking the fasting and physiological states, but decreases the POMC activity at high glucose levels (10 mM), mimicking a fed state [165] in electrophysiological recordings. The state-dependent adiponectin mechanism of action may act differentially on different molecular pathways: Adiponectin inhibits POMC neurons at high glucose via AMPK signaling, while it activates POMC neurons at low glucose via PI3-K signaling [165]. In contrast to the glucose-dependent effect in POMC, adiponectin enhances the activity of inhibitory GABA-ergic NPY neurons in a glucose-independent fashion [166]. Altogether, at low glucose conditions, adiponectin suppresses orexigenic NPY neurons and activates anorexigenic POMC neurons to attenuate appetite and food intake under conditions of fasting or low blood glucose. On the other hand, at high glucose levels, feeding behavior is nullified [165] as adiponectin inhibits both anorexigenic and orexigenic activities. Since leptin resistance and hypoadiponectinemia are symptomatic in obese and type 2 diabetic subjects, disrupted interplay of leptin and adiponectin may collectively impair anorectic actions and thus promote caloric intake and energy accumulation in obese and diabetic conditions. Hypoadiponectinemia is often documented in patients receiving atypical antipsychotics medication, including olanzapine and clozapine, in association with increased adiposity and hyperleptinemia [68,167,168]. Specifically, clozapine medication leads to body weight gain, high triglyceride profile, and hypoadiponectinemia [169,170]. GABA-facilitated orexigenic NPY activation and the subsequent suppression of anorexigenic POMC activity is suggested to be a potential mechanism of olanzapine-induced obesity [171]. The disrupted hypothalamic control of energy homeostasis may, therefore, lead to hyperleptinemia and hypoadiponectinemia. Still, some atypical antipsychotics, including risperidone and quetiapine, do not affect adiponectin levels [168,172,173,174].

AdipoR1 is expressed in dopaminergic neurons in the VTA [175]. The adiponectin receptor expression implicates the crosstalk of adiponectin and dopamine signaling pathways. Hedonic behaviors and affective behaviors are intertwined by dopamine signaling [176,177,178,179]. Recent research dissecting the role of adiponectin receptor in mediating anxiety reveals that intra-VTA infusion of adiponectin or the adiponectin receptor agonist AdipoRon suppresses dopaminergic neuron firing in an AdipoR1-dependent manner [175]. However, impaired adiponectin signaling due to adiponectin haploinsufficiency or AdipoR1 ablation increases dopaminergic activity and anxiety behavior. Adiponectin action shares similarities with the inhibitory action of leptin on the VTA dopaminergic neurons. Importantly, anxiety symptoms are often comorbid with metabolic disorders [180], where hypoadiponectinemia is indicative in obese and type 2 diabetic subjects [140,141,181]. It is speculated that the interplay of leptin and adiponectin may also exist in the VTA dopaminergic neurons to modulate reward and affective behaviors.

Patients with type 2 diabetes or dementia display decreased adiponectin levels [182,183,184]. High fat diet-induced and streptozotocin-induced diabetic conditions reduce AdipoR1 and AdipoR2 expressions in the hippocampus [27]. Adiponectin knockout reduces proliferating cells, differentiating cells, and cell survival in the hippocampus [185]. Adiponectin stimulates the proliferation of hippocampal progenitors through p38MAPK/GSK-3β/β-catenin cascade [157]. Moreover, adiponectin deficiency reduces the dendritic length, branching, and spine density of dentate granule neurons, particularly in early-born granule neurons in the hippocampal dentate gyrus [185]. Low levels of adiponectin are associated with cognitive dysfunction [184]. Chronic adiponectin deficiency impairs spatial memory and learning and induces anxiety-like behavior [19]. Moreover, AdipoR1 knockdown causes metabolic dysfunction and neurodegeneration in an association with the cognitive deficit in Morris water maze [186]. Overexpression of adiponectin in the brain [25] or infusion of recombinant adiponectin into the cerebral ventricle induces antidepressant effects [158,187,188]. The antidepressant effect could be linked to the activation of the AdipoR1/APPL1/AMPK pathway [25]. Rosiglitazone, a blood–brain barrier-impermeable PPARγ-selective agonist, enhances adiponectin levels and elicits antidepressant- and anxiolytic-like effects in wild-type mice, but not adiponectin-deficient mice or mice pretreated with PPARγ-selective antagonist [189].

The pro-cognitive effect of adiponectin in AD could be linked to its anti-inflammatory effect and enhanced effects on synaptic plasticity. Globular adiponectin predominantly binds to AdipoR1 and inhibits nuclear factor-κB (NF-κB) activation in macrophages, which in turn, suppresses its production of pro-inflammatory cytokines [190,191]. Therefore, adiponectin may reduce the extracellular deposition of amyloid-β via its suppressive effect on microglial activation. Moreover, adiponectin attenuates streptozotocin-induced Tau hyperphosphorylation and cognitive deficits through PI3K/Akt/GSK-3β pathway [192]. Activating AMPK can suppress GSK-3β action on Tau phosphorylation, whereas chronic adiponectin deficiency fails to phosphorylate AMPK, which in turn, enables GSK3β action on promoting Tau hyperphosphorylation, and subsequently results in AD-like neuropathology [19]. Nine-month-old adiponectin-deficient, 5×FAD mice show microglia activation together with elevated TNFα and IL-1β levels in the cortex and hippocampus [193]. In accordance with the previous study, an in vivo study illustrates that globular adiponectin exerts anti-inflammatory effects on microglia by reducing IL-1β, IL-6, and TNFα [33]. Pre-treatment with adiponectin can diminish TNFα and IL-1β release in vitro [193]. Adiponectin potentially exerts anti-inflammatory action on microglia via AdipoR1/NF-κB signaling [33,193]. Other studies have further demonstrated that adiponectin exhibits anti-inflammatory response dependent on PPARγ [194] or IL-4/STAT6 signaling pathway [191]. Recently, an ex vivo study has demonstrated that adiponectin exhibits a beneficial effect on hippocampal synaptic plasticity in 5×FAD mice. Acute perfusion for 10-min or 2-h incubation of 2.7 nM adiponectin can induce LTP in the hippocampal CA1 region in five to six months old 5×FAD mice. Acute incubation of adiponectin also increases expressions of AdipoR1 and AdipoR2, increases protein expressions of GluA1, GluN1, GluN2B, and PSD-95 as well as elicits anti-apoptotic and anti-inflammatory effects [195]. These findings suggest that adiponectin inhibits neuronal apoptosis and inflammatory mechanisms and promotes hippocampal long-term potentiation. Taken together, these data have suggested the neuroprotective and neurogenic effects of adiponectin in the hippocampus (Table 1).

2.3. Chemerin
Chemerin is a novel adipokine that acts autocrine, paracrine, and endocrine on different tissues [196] by binding to either chemokine-like receptor 1 [197], chemokine receptor-like receptor 2 [198] or G protein-coupled receptor 1 [199]. Chemerin is highly expressed in white adipose tissue [200] and acts as a pro-inflammatory cytokine [201] and anti-inflammatory cytokine. It promotes adipogenesis [200], angiogenesis [202], and inflammation [203]. Clinical study has shown that change of chemerin levels is linked to obesity because the circulating levels of chemerin is positively correlated with high body-mass index and elevated obesity-related biomarkers [204,205,206]. Similarly, high fat diet-induced obese mice display an increase in plasma chemerin levels, and this increase can be reduced by overnight fasting [207]. Another study has shown that chemerin administration exacerbates the glucose intolerance in obese and diabetic mice by reducing hepatic glucose uptake [208]. Chemerin deficiency results in insulin resistance in adipose tissue and liver, leading to elevated hepatic glucose production and increased blood glucose levels [209]. On the other hand, chemokine-like receptor 1 knockout mice have reduced glucose uptake in adipose tissue and skeletal muscle [210], whereas high-fat diet further exacerbates glucose intolerance, hyperinsulinemia and enhances insulin resistance in these mice [211].

Activation of the chemerin signaling pathway plays a vital role in the neuroendocrine axis by regulating appetite. Chemerin receptors are highly expressed in multiple rodent brain regions, including the prefrontal cortex, hippocampus, and hypothalamus [212]. Continuous intracerebral infusion of chemerin into photoperiodic-sensitive F344 rats can promote food intake [213], whereas chemokine-like receptor 1 deficiency reduces food intake and body weight [210]. Chemerin can also aggravate glucose intolerance [208]. Consistently, clinical data indicate that circulating chemerin levels are increased in patients with obesity, diabetes, and cardiovascular diseases [214].

A recent study has shown that intranasal administration of human recombinant chemerin (rh-chemerin) exerts neuroprotective effects in a rat model of neonatal hypoxia-ischemia brain injury [215]. Intranasal treatment with chemerin significantly reduces infarct volume and attenuates developmental delay 24 h after hypoxic-ischemic encephalopathy. Chemerin treatment significantly improves cognitive and sensorimotor performance in animals with hypoxic-ischemic encephalopathy. Moreover, recombinant chemerin treatment significantly reduces apoptosis and the expressions of pro-apoptotic markers [215], suggesting a neuroprotective role of chemerin. Chemerin signaling is proposed to mediate neuro-inflammatory action in the brain. It is reported that the expression of chemokine like receptor 1 (CMKLR1) is upregulated in AD patients, suggesting the role of central chemerin signaling in the progression of AD [216]. Systemic lipopolysaccharide administration is known to upregulate CMKLR1 expression and promote neuroinflammation [216]. This study has reported that CMKLR1 and Aβ42 are colocalized in hippocampal neurons of APP/PS1 AD mice, and CMKLR1 is involved in Aβ processing and clearance. CMKLR1 is detected in the hippocampus and prefrontal cortex, two critical brain regions involved in the pathology of depression [217]. Intracerebral administration of chemerin elicits antidepressant effects [218]. In the lipopolysaccharide-induced depression mouse model, intracerebral administrations of chemerin receptor agonist: Eicosapentaenoic acid-derived resolvins E1 (1 ng) or E2 (10 ng) produce antidepressant effects depending on ChemR23/mTORC1 pathway in the medial prefrontal cortex and hippocampal dentate gyrus [218] (Table 1), suggesting activating chemerin signaling could be a novel antidepressant target.

2.4. Apelin
Apelin, a peptide hormone secreted by adipocytes, is involved in insulin secretion [219], glucose and lipid metabolism [220], angiogenesis [221], blood pressure regulation [222], and food intake [223]. Apelin has similar properties as physical exercise does in metabolism, and so given entitled it as an exerkine [224]. Apelin can be proteolytically cleaved into several bioactive forms, including apelin-13, -17, and -36, as well as the pyroglutaminated apelin-13 isoform [225]. Apelin receptors are widely distributed in rodent brain and systemic tissues [226].

Apelin is necessary for balancing the fat composition and promoting insulin sensitivity. Apelin-knockout mice exhibit obese and diabetic symptoms, including increased abdominal fat mass, glucose intolerance, hyperinsulinemia, and hypo-adiponectinemia [227]. High-fat diet and high-sucrose consumption aggravate glucose and insulin intolerance in apelin-deficient mice [228]. Clinical study has reported a positive correlation between plasma insulin levels and apelin expression in adipocytes from obese subjects. Given this insulin-sensitizing property, apelin has become a promising therapeutic target for treating obesity and diabetes. Single intravenous injection of 200 pmol/kg Pyr(1)-apelin-13 can improve glucose intolerance in high-fat diet-induced obese and insulin-resistant mice [229]. Chronic apelin treatment (two to four weeks) improves insulin sensitivity, lowers blood glucose levels, and protect the animals from hyperinsulinemia and glucose intolerance in mice with obesity or insulin resistance [228,230]. Apelin treatment can also significantly reduce adiposity and plasma triglycerides [230]. Apelin is involved in lipid metabolism by inhibiting isoproterenol-induced lipolysis in cultured adipocytes [227]. Moreover, exogenous apelin reduces the number of differentiated adipocytes and increases the size of lipid droplets inside the cells, suggesting that apelin might suppress lipolysis [231]. In vitro studies reveal that apelin-13 and [Pyr1]-apelin-13 improve glycemia in an AMPK/eNOS-dependent [229] and PI3K/Akt-dependent [232] pathways respectively. These findings have collectively suggested that apelin treatment could be useful in reducing adiposity, improving insulin sensitivity, and improving diabetic conditions.

Similar to other adipokines, apelin exhibits anti-inflammatory properties [232] and possesses neuroprotective effects [233]. In an ischemia/reperfusion (I/R) stroke rat model, the post-stroke intracerebral injection of apelin-13 can significantly reduce the infarct volume [234]. Similarly, intracerebral infusion of apelin-13 significantly decreases blood–brain barrier permeability and increases vascular endothelial growth factor levels in post-stroke mice [235]. Furthermore, post-stroke treatment with intranasal apelin-13 for three days can reduce infarct volume, reduce neuronal apoptosis, suppress inflammation, and increase angiogenesis [236]. In mice with traumatic brain injury, intracerebral administration of apelin-13 reduces brain damage via suppressing autophagy [237]. Apelin-13 also elicits an anti-inflammatory effect by inhibiting microglia and astrocyte activation and upregulates hippocampal BDNF and TrkB expression in streptozotocin-induced sporadic AD rats. Furthermore, the apelin-13 treatment also promotes learning and memory performance, as evidenced by its effect on improving novel object recognition and spatial recognition through the BDNF/TrkB pathway [238]. In a rat model of depression, apelin-13 treatment elicits antidepressant effect and improves recognition memory via activating phosphatidylinositol 3-kinases (PI3K) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathways. The hippocampus is thought to be the critical brain region mediating the antidepressant-like response of apelin [239,240]. Similarly, intracerebral infusion of apelin-13 can ameliorate depression-like phenotypes in rats subjected to chronic restraint stress. Apelin-13 can also suppress hypothalamic-pituitary-adrenal axis hyperactivity, promote hippocampal BDNF expression, and restore hippocampal glucocorticoid receptor functions in rats with chronic stress [241] (Table 1).

2.5. Visfatin (Nicotinamide phosphoribosyltransferase, NAMPT)
Nicotinamide phosphoribosyltransferase (NAMPT) is an enzyme which catalyzes the biosynthesis of nicotinamide adenine dinucleotide (NAD+) in mammals [242]. There are two isoforms of NAMPT: Intracellular NAMPT (iNAMPT) and extracellular NAMPT (eNAMPT or visfatin) [242]. Growing evidence shows that NAD+/NADH metabolism in adipose tissue is linked to obesity and insulin resistance. In humans, visceral adipose NAMPT expression and serum NAMPT levels are positively correlated with obesity [243]. In mice, adipose NAMPT expression and NAD+ contents are markedly reduced by high-fat diet feeding [244,245], but increased by caloric restriction [246,247]. Adipocyte-specific Nampt knockout mice show severe insulin resistance in multiple organs under a chow-fed condition, which is independent of body weight and adiposity [248]. Loss of Nampt causes adipose tissue inflammation, increases plasma free fatty acid concentrations, and decreases adiponectin. Notably, oral administration with nicotinamide mononucleotide, a key NAD+ intermediate, can restore adipose tissue NAD+ biosynthesis and significantly restore insulin resistance, plasma adiponectin and free fatty acid concentrations in adipocyte-specific Nampt knockout mice. On the other hand, visfatin is secreted from white adipose tissue through sirtuin1 (SIRT1)-mediated deacetylation of iNAMPT [249]. At present, it remains uncertain whether visfatin can cross the blood–brain barrier. However, adipose-secreted visfatin serves as a neuroendocrine factor. Adipose tissue-specific Nampt knockout mice display a significant reduction in circulating visfatin, as well as reduced hypothalamic NAD+ content and SIRT1 activity [249]. On the other hand, adipose-specific Nampt knock-in mice show increases in hypothalamic NAD+ content, SIRT1 activity, and neural activity in response to fasting. Therefore, adipose-secreted visfatin has a strong implication on modulating brain functions.

Visfatin protects neurons against ischemia-induced injury because NAMPT overexpression can reduce infarct volume and improve long-term neurologic outcomes [250]. In a transient global cerebral ischemia model with 20-min carotid arteries occlusion, intracerebral infusion of 100 ng visfatin in the hippocampal CA3 region during cerebral reperfusion can reduce the caspase-3 activation and Bax/Bcl-2 ratio [251]. Visfatin can significantly reduce apoptosis and necrotic cell death in the CA1 region of the hippocampus, with improved memory deficits in I/R rats. The suppressed pro-apoptotic and enhanced anti-apoptotic mechanisms could contribute to the neuroprotective effects of visfatin [250]. In another study, transgenic mice overexpressing NAMPT globally increase NAD+ content and neuronal survival in the hippocampal dentate gyrus [252]. These mice also display better learning and memory performance in the water maze test upon middle cerebral artery occlusion. Post-ischemic intraperitoneal administration with nicotinamide mononucleotide for seven days can improve adult hippocampal neurogenesis [252]. Nicotinamide mononucleotide and NAD+ promotes proliferation and differentiation of neural stem cells in a NAMPT/NAD+/SIRT manner [252]. An in vitro study has concluded that cultured glia, but not neuron, can secrete visfatin under oxygen-glucose deprivation stress. Treatment of wild-type visfatin, but not H247A-mutant enzymatic-dead visfatin, can significantly attenuate oxygen-glucose deprivation-elicited cell death in both cultured mouse neuron and glia. Treatment of neutralizing antibody can, in turn, abolish the protective effect of extracellular visfatin on cell viability [253].

Although the neuroprotective benefits of visfatin towards neurodegenerative diseases require further investigation, growing evidence has indicated that NAD+ administration can improve cellular energetics and extend life span in rodents [254]. The evidence leads to the idea that the administration of NAD+ precursors, including nicotinamide mononucleotide and nicotinamide riboside, is a potential treatment to forestall disease progress in AD by improving brain energetics [255]. In the AD rat model with an intracerebral infusion with Aβ amyloid, intraperitoneal administration of 500 mg/kg nicotinamide mononucleotide improves learning and memory performance in water maze task [256]. Nicotinamide mononucleotide also attenuates Aβ oligomer-induced neuronal cell death, prevents long-term potentiation deficit, restores NAD+ and ATP levels, and eliminates reactive oxygen species in organotypic hippocampal slices [256]. Moreover, nicotinamide riboside treatment exhibits pro-cognitive function by increasing cortical NAD+ content and restoring long-term potentiation deficit in the hippocampal CA1 region of the Tg2576 AD mouse model. This study has suggested that treatment upregulating the NAMPT/NAD+ axis could prevent Aβ accumulation in the brain [257] (Table 1).

3. Novel Adipocyte-Derived Messengers on Brain Health
Lipokine refers to fatty acids that act like hormones and modulate lipid metabolism [258]. Notably, adipose tissue, which is one of the systemic sites with active lipid metabolism, secretes various lipids into the bloodstream to communicate with distant organs. Coincidentally, alterations in lipid metabolism may implicate the onset of brain diseases. For example, apolipoprotein E (ApoE) mediates systemic cholesterol metabolism and acts as a cholesterol carrier to neurons in the central nervous system. Human carriers of mutated apolipoprotein E allele ϵ4 are associated with an increased risk of AD [259]. Moreover, post-mortem studies have shown that AD patients display abnormal levels of ceramides, n-3 polyunsaturated fatty acids (PUFA), and PUFA-derived signaling lipids [260,261,262,263,264].

Lipokines, including monounsaturated palmitoleic acid and lysophosphatidic acid (LPA can exert endocrine effects on systemic tissues and have potential crosstalk with the central nervous system. Palmitoleic acid is a highly abundant fatty acid in the serum. Its circulating levels fluctuate dependent on metabolic states. Obese children and adults exhibit a higher plasma palmitoleic acid content compared to healthy control [265,266]. Besides, the change of palmitoleate could be associated with an increased risk of obesity, dyslipidemia, and insulin resistance [265,266,267,268]. On the other hand, lysophospholipid is a prominent class of lipid signaling molecules, whereas LPA is a crucial member. Circulating LPAs are synthesized by autotaxin, a phosphodiesterase produced by adipocytes [269]. Circulating autotaxin levels increase in obesity and insulin resistance [270,271,272,273,274,275,276], which is positively correlated with an increase in circulating lysophosphatidic acid [277,278]. A high-fat diet can perturb lipid composition in the brain. The altered lipid composition is evidenced by a surge of palmitoleic acid composition in the mouse brain after 14 days of high carbohydrate and high fatty acid diets [279]. Congruently, high-fat diet causes a significant elevation of LPA in mouse cortex after eight weeks of high-fat diet [280]. Importantly, over-nutritious food has detrimental effects on brain plasticity because brain diseases could be linked to dysregulated lipid metabolism [281,282,283,284,285,286]. The effects of palmitoleic acid and lysophosphatidic acid on brain health warrant further investigation.

3.1. Palmitoleic Acid (16:1n7)
Palmitic acid (16:0) is the most common saturated fatty acid in the human body. It can be consumed through diet or synthesized from other fatty acids, carbohydrates, and amino acids endogenously [287]. Under normal physiological conditions, palmitic acid accumulation is prevented by desaturation to palmitoleic acid (16:1n7) or by elongation to stearic acid (18:0), then further desaturation to oleic acid (18:1) [288,289]. Abnormal levels of palmitic acid have been documented in neurodegenerative diseases [290,291,292] that are related to dysregulated palmitic acid biosynthesis. Palmitoleic acid, a monounsaturated fatty acid, primarily originates from stearoyl-CoA desaturase 1-mediated de novo lipogenesis from palmitic acid in humans [287]. Palmitoleic acid is highly abundant in serum and adipose tissues [293]. cis-palmitoleate has been associated with increased insulin sensitivity and decreased lipid accumulation in the liver [258]. Various animal models have illustrated that cis-palmitoleate reduces the expressions of pro-inflammatory cytokines and adipokines in association with metabolic syndromes [258,294,295]. In vitro study also shows that palmitoleic acid increases lipolysis and lipase content in white adipose tissue in a PPARα-dependent manner [296]. Other than adipose tissues, palmitoleic acid can enhance whole-body glucose disposal [297] and improve circulating lipid profiles in both rodents and humans [298]. Therefore, palmitoleic acid is considered a lipokine.

Fatty acid-binding proteins (FABP) are lipid chaperones that regulate lipid trafficking and responses in cells [299,300]. In humans, circulating adipose-derived fatty acid-binding protein (A-FABP) levels are substantially higher than other adipokines, including leptin, resistin, TNF-α, and IL-6 [301,302,303]. Circulating A-FABP is markedly increased in both obese men and women [304], suggesting that A-FABP may involve in modulating insulin sensitivity and lipid metabolism in distant organs. Of note, A-FABP is also considered as an adipokine, which is secreted from adipocyte-derived exosomes by exocytosis [305]. Critically, deficiencies in A-FABP and epidermal fatty acid-binding protein (E-FABP) can activate SCD1 activity, leading to a subsequent elevation in palmitoleate concentration in adipose tissue [306,307]. A-FABP deficient mice exhibit improvement in systemic glucose, lipid metabolism and insulin resistance in association with diet-induced and genetically-disposed obesity [308]. The A-FABP and E-FABP double mutant mice are resistant to diet-induced obesity, insulinemia, type 2 diabetes, dyslipidemia, and fatty liver disease [309,310]. The dysregulated SCD1-mediated de novo synthesis of palmitoleic acid enhances whole-body glucose and fatty acid metabolism [311].

Although it requires more solid evidence to demonstrate the effect of adipocyte-secreted palmitoleic acid and A-FABP on brain health, it is reported that stearoyl-CoA desaturase activity and levels of palmitoleic acid in the brain are associated with AD [312]. Liquid chromatography-mass spectrometry analysis has revealed elevated levels of several monounsaturated fatty acids, including palmitoleic acid, in the mid-frontal cortex, temporal cortex, and hippocampus of AD patients as compared to their age-matched counterparts [312]. This increase is strongly associated with cognitive dysfunction and the increased expression of stearoyl-CoA desaturase in the brain [266,313,314,315,316,317]. Further studies have shown that AD patients have increased expressions of various stearoyl-CoA desaturase isoforms, including SCD-1 [312]. Coherently, stearoyl-CoA desaturase activity is negatively correlated to cognitive measures [312]. Levels of free palmitoleic acid and the desaturation index are decreased in frontal cortices in aged dogs treated with antioxidant, and vice versa [318]. The study implicates that altering stearoyl-CoA desaturase activity and reducing palmitoleic acid levels in the brain may improve cognitive performance [318].

3.2. Lysophosphatidic Acid
Neuroinflammation is commonly associated with type 2 diabetes [319], and obesity [320]. High-fat diet feeding results in profound central and peripheral inflammation [321,322]. Autotaxin is a lysophospholipase that synthesizes lysophosphatidic acid (LPA). Autotaxin is also regarded as an adipokine due to its role in promoting adipocyte differentiation [269]. Evidence suggests that the autotaxin-mediated LPA biosynthesis contributes to the majority of extracellular LPA, in which adipocyte-specific autotaxin contributes to most of the circulating LPA [269,272]. Further investigations suggest that circulating LPA and autotaxin levels are linked to adipocyte differentiation and obesity [269,271]. Autotaxin expression is upregulated in obese patients and obese db/db mice due to the accumulation of triglycerides in the adipocytes [271]. A recent study has reported that adipose-derived autotaxin serves as an inflammatory cytokine of diet-induced obesity [323].

LPA signaling mediates inflammation [324], angiogenesis [325], brain development [326], and neurogenesis [327] in the brain. Specifically, LPA exerts a pleiotropic effect on various brain cell types, including neurons, astrocytes, microglia, and oligodendrocytes that show LPA receptors expression [328]. LPA promotes neuronal differentiation in cortical neural progenitor cells through LPA1 receptor/Gi/o pathway [329], whereas axonal branching is induced in hippocampal cell cultures through LPA3 receptor/Gq/Rho family GTPase 2 (Rnd2) pathway [330]. Mainly, LPA1 is essential in mediating synaptic plasticity and learning. In vitro studies have shown that overexpression of LPA1 increases dendritic spine density and size [331], potentially through protein kinase C (PKC)/Rho and PKC/Rac cascades [332,333]. It is speculated that LPA1 deficiency can cause schizophrenia-like behaviors, including impaired spatial memory retention and increased anxiety-like behavior [334,335,336]. Furthermore, the role of LPA and its receptors in anxiety-like behavior and learning has been confirmed by later studies using LPA1-null mice. These mice show normal survival but display aberrant hippocampal neurogenesis and decreased BDNF levels [327], as well as increased anxiety-like behavior and memory deficits [337]. LPA mediates astrocyte proliferation through the LPA1 receptor [338]. Interestingly, LPA promotes astrocyte-neuronal crosstalk through laminin-mediated EGFR/MAPK signaling to facilitate neuronal differentiation [339]. LPA triggers microglial migration through a Ca2+-dependent K+ channel [340,341], and reduces oxidative stress [342,343]. Moreover, LPA can promote the retraction of oligodendrocyte processes in mature oligodendrocytes [344] as well as promotes the formation of oligodendrocyte processes in differentiating oligodendrocytes [345].

In addition to a metabolic disorder, an altered systemic lipid metabolism may have a neurological impact [346] through autotaxin-LPA signaling. Clinical study has reported that mild cognitive impairment and AD patients have significantly higher levels of autotaxin in cerebrospinal fluid [347]. Furthermore, the autotaxin levels are positively correlated to neuroinflammatory markers, β-amyloid, and tau in the cerebrospinal fluid [347]. In vitro study has shown that LPA could increase Aβ production by upregulating the expression of β-secretase expressions in the N2a neuroblastoma cell line expressing wild-type presenilin 1 and Swedish mutant APP [348]. Potentially, LPA-induced BACE1 promoter activation is mediated by PKCδ/MEK/MAPK/p90RSk/CREB signaling cascades [348,349,350,351,352,353]. Moreover, LPA may be involved in tau hyperphosphorylation and paired helical filaments formation, which are the pathological patterns in AD brains through Gα12/13/RhoA/Rock/GSK-3β pathway [354,355], suggesting potential connection among LPA, microfilament dynamics, and AD pathogenesis.

4. Conclusions
It is an emerging research field to understand the functions of different adipokines in regulating eating behavior, hippocampal plasticity, and neuronal protection. This review has denoted five adipokines (leptin, adiponectin, chemerin, apelin, and visfatin) and two lipokines (palmitoleic acid and lysophosphatidic acid) (Figure 1). The review has summarized the currently available evidence for their novel function in the brain. First, it is evident that the aberrant adipokine production not only renders the susceptibility to metabolic syndromes in genetically deficient rodent models of various adipokines but also the vulnerability to neurodegeneration, especially in models of impaired leptin-signaling. Accumulated evidence has indicated that diet-induced obese or diabetic rodent models show abnormal levels of leptin, adiponectin, chemerin, apelin, and visfatin. Notably, circulating adiponectin and visfatin levels are reduced in diet-induced obesity, with associated impairments in hippocampal plasticity and cognitive behaviors [356]. Due to the multifaceted effect of adipokines on systemic and brain health, dysregulated adipokine secretion could be one of the causes that underlie the comorbidity of metabolic syndromes with neurodegenerative disorders [357,358]. Thus, all these investigations have highlighted the prominent roles of adipokines on brain health. Second, evidence also shows that leptin and adiponectin can elicit their action directly in the brain by crossing the blood–brain barrier. Leptin is not only a satiety regulator through anorexigenic and dopaminergic controls, but ample evidence also supports its role in promoting neuroplasticity in the hippocampus [12]. On the other hand, adiponectin is a chief metabolic regulator in glucose and fatty acid metabolism with insulin-sensitizing ability in both peripheral and central systems. Current findings have suggested the direct effect of adiponectin on synaptic plasticity [195,359] and microglial activation [193]. Both exogenous leptin and adiponectin can exert pro-cognitive effects in mouse models. Besides, leptin and adiponectin signaling pathways are defective in AD brains [360]. Hence, increasing leptin and adiponectin signaling can be a potential therapeutic target for AD [361,362]. Third, emerging literature has also revealed the central function of three novel adipokines: Chemerin, apelin, and visfatin. Inflammatory response and apoptosis are typical in neurodegenerative diseases [363,364] and ischaemic stroke [365,366]. These novel adipokines are potential therapeutic targets, which modulate anti-inflammatory and anti-apoptotic effects in the hippocampus. Finally, this review has highlighted lipokines are a lipid signaling molecule secreted by adipocytes with potential endocrine effect acting on the brain [367]. Still, the potential of lipokines is mostly unknown, future studies will be required to illustrate its properties and function in neuroplasticity and cognitive functions.

Overall, adipokines emerge as viable therapeutic targets towards neurodegenerative diseases. Adipokine-based therapeutic approaches could be future pharmaceuticals to obliterate neurodegenerative disorders. More in-depth investigations on the above-mentioned adipokines and its crosstalk with the brain can open up new therapeutic targets to treat neurodegenerative diseases.

Author Contributions
T.H.-y.L. wrote the manuscript. S.-y.Y., K.K.y.C., R.L.-c.H., and P.M.-f.S. revised and edited the manuscript.

Funding
This work is supported by the Hong Kong Research Council Early Career Scheme (project No. 25100217) and National Natural Science Foundation of China (Project No. 81801346) awarded to S.-y.Y.

Conflicts of Interest
The authors declare no conflict of interest.

Figure 1 Potential mechanism of adipokine actions on brain health. Adiponectin and leptin can cross the blood–brain barrier to promote neuroplasticity. Other adipokines and lipokines show profound effects on mediating neurogenic and neuroinflammatory mechanisms.

ijms-20-05638-t001_Table 1Table 1 Effects of adipokines on neuroplasticity, neuroprotection, and cognitive behaviors.

Animal Model	Treatment	Delivery Route	Neurological Effects	References	Year	

Leptin
	
C57BL/6J
(healthy)	mice	14 days 1 mg/kg recombinant rat leptin	i.p.	
Increased cell proliferation and survival in the hippocampal dentate gyrus


	Garza et al. [24]	2008	
C57BL/6JJ
(healthy)	mice	30 min after injecting 1 mg/kg leptin	i.p.	
Reduced depressive behavior in forced swim and tail suspension tests


	Liu et al. [127]	2010	
4 and 12 m.o. SAM-P8	mice	0.25–0.5 µg mouse recombinant leptin post-training	Intra-hippo	
Improved memory retention in T-maze footshock avoidance and step-down inhibitory avoidance.


	Farr et al. [118]	2006	
Sprague-DawleyJ
(healthy)	rats	1.0 µM leptin	Intra-DG	
Enhanced LTP


	Wayner et al. [131]	2004	
6 m.o. TgCRND8 AD	mice	8 weeks 20 µg leptin daily	Systemic infusion by osmotic pump	
Improved object recognition

Improved fear-associated learning


	Greco et al. [133]	2010	
Aβ1-42-assaulted 	rat	10 days 1 µg leptin daily	i.c.v.	
Improved spatial memory in Y maze and water maze

Enhanced LTP


	Tong et al. [134]	2015	

Adiponectin
	
HFD-induced stress and naïve C57BL/6J	mice	0.1–0.3 µg globular adiponectin	i.c.v	
Reduced depressive behavior


	Liu et al. [158]	2012	
C57BL/6J
(healthy)	mice	Overexpression of adiponectin by adenovirus	i.c.v	
Reduced depressive behavior in forced swim test


	Yau et al. [25]	2014	
Sedentary or environmentally enriched C57BL/6J	mice	1 mg/kg globular adiponectin	i.v.	
Reduced depressive behavior in forced swim test


	Nicolas et al. [187]	2015	
Corticosterone-induced stress C57BL/6J	mice	0.3 µg globular adiponectin	i.c.v.	
Reduced microglial response

Reduced pro-inflammatory cytokine secretion from microglia


	Chabry et al. [188]	2015	
Adipo+/+ & +/- C57BL/6J mice	mice	10 mg/kg rosiglitazone 1 or 3 h before test	i.p.	
Reduced depressive and anxiety-like behavior


	Guo et al. [189]	2017	
STZ-infused Sprague–Dawley	rats	0.1 µg/g adiponectin	i.c.v.	
Improved learning and memory

Increased hippocampal dendritic and spine complexities

Reduced tau hyperphosphorylation


	Xu et al. [192]	2018	

Chemerin
	
Hypoxic-ischemic encephalopathy in P10
Sprague-Dawley	rats	9 μg/kg rh-chemerin, 3 doses	i.n.	
Better learning and memory functions

Reduced apoptosis


	Zhang et al. [215]	2019	
LPS-induced depression
BALB/c	mice	500 ng chemerin	i.c.v.	
Reduced depressive behavior in forced swim and tail suspension tests


	Deyama et al. [218]	2018	
LPS-induced depression
BALB/c	mice	Resolvin E1	i.c.v. (1 ng) and bilateral intra-mPFC and intra-DG (50 pg/side)	
Reduced depressive behavior in forced swim and tail suspension tests


	Deyama et al. [218]	2018	
LPS-induced depression
BALB/c	mice	10 ng resolvin E2 	i.c.v.	
Reduced depressive behavior in forced swim and tail suspension tests


	Deyama et al. [218]	2018	

Apelin
	
Cerebral I/R Wistar	rats	50 ng/kg apelin-13 post-ischemia	i.c.v.	
Reduced infarct volume


	Xin et al. [234]	2015	
Cerebral I/R
AQP4+/+ & -/-	mice	50 ng/kg apelin-13 post-ischemia	i.c.v.	
Decreased BBB permeability


	Chu et al. [235]	2017	
Cerebral I/R
C57BL/6J	mice	4 mg/kg, 3 doses for three days post-ischemia	i.n.	
Reduced infarct

Reduced neuronal apoptosis


	Chen et al. [236]	2015	
TBI CD-1	mice	50 µg apelin-13	i.c.v.	
Suppressed autophagy


	Bao et al. [237]	2015	
STZ-infused AD Sprague–Dawley	rats	2 µg, daily for 4 weeks	i.c.v.	
Improved object and spatial recognition

Suppressed neuroinflammation


	Luo et al. [238]	2019	
Forced-swimming stressed Wistar	rats	2 µg, three doses in 24 h before FST	i.c.v.	
Reduced hedonic deficit in learned helplessness

Improve object recognition


	Li et al. [238]	2016	
Chronic water-immersion restraint stress Wistar	rats	2 µg, daily for 7 days	i.c.v.	
Reduced depressive behavior in sucrose preference and tail suspension tests


	Dai et al. [241]	2018	

Visfatin
	
Cerebral I/R	mice	pThy1:NAMPT	transgenic	
Reduced infarct volume

Reduced neurological deficits

Increased striatal and corpus callosum myelination


	Jing et al. [250]	2014	
Cerebral I/R Wistar	rats	100 ng visfatin during reperfusion	Intra-CA	
Suppressed apoptosis

Enhanced anti-apoptotic mechanism


	Erfani et al. [251]	2015	
Cerebral I/R C57BL/6J	mice	pIRES2::NAMPT	transgenic	
Improved learning and memory


	Zhao et al. [252]	2015	
Cerebral I/R C57BL/6J	mice	500 mg/kg NMN daily for 7 days	i.p.	
Promoted hippocampal neurogenesis


	Zhao et al. [252]	2015	
Aβ-infused AD Sprague-Dawley	rats	500 mg/kg NMN daily for 10 days	i.p.	
Improved learning and memory


	Wang et al. [256]	2016	
Tg2576 AD	mice	250 mg/kg nicotinamide riboside daily for 3 months	i.p.	
Improved object recognition

Increased cortical NAD+

Abolished long-term potentiation deficits


	Gong et al. [257]	2013
==== Refs
References
1. Kershaw E.E.  Flier J.S.   Adipose tissue as an endocrine organ J. Clin. Endocrinol. Metab. 2004 89 2548 2556 10.1210/jc.2004-0395 15181022 
2. Han S.  Sun H.M.  Hwang K.C.  Kim S.W.   Adipose-derived stromal vascular fraction cells: Update on clinical utility and efficacy Crit. Rev. Eukaryot. Gene Expr. 2015 25 145 152 10.1615/CritRevEukaryotGeneExpr.2015013057 26080608 
3. Warner A.  Mittag J.   Brown fat and vascular heat dissipation: The new cautionary tail Adipocyte 2014 3 221 223 10.4161/adip.28815 25068090 
4. Cedikova M.  Kripnerova M.  Dvorakova J.  Pitule P.  Grundmanova M.  Babuska V.  Mullerova D.  Kuncova J.   Mitochondria in white, brown, and beige adipocytes Stem Cells Int. 2016 2016 6067349 10.1155/2016/6067349 27073398 
5. Duncan R.E.  Ahmadian M.  Jaworski K.  Sarkadi-Nagy E.  Sul H.S.   Regulation of lipolysis in adipocytes Annu. Rev. Nutr. 2007 27 79 101 10.1146/annurev.nutr.27.061406.093734 17313320 
6. Choe S.S.  Huh J.Y.  Hwang I.J.  Kim J.I.  Kim J.B.   Adipose tissue remodeling: Its role in energy metabolism and metabolic disorders Front. Endocrinol. 2016 7 30 10.3389/fendo.2016.00030 27148161 
7. Cook K.S.  Min H.Y.  Johnson D.  Chaplinsky R.J.  Flier J.S.  Hunt C.R.  Spiegelman B.M.   Adipsin: A circulating serine protease homolog secreted by adipose tissue and sciatic nerve Science 1987 237 402 405 10.1126/science.3299705 3299705 
8. Zhang Y.  Proenca R.  Maffei M.  Barone M.  Leopold L.  Friedman J.M.   Positional cloning of the mouse obese gene and its human homologue Nature 1994 372 425 432 10.1038/372425a0 7984236 
9. Rosen E.D.  Spiegelman B.M.   What we talk about when we talk about fat Cell 2014 156 20 44 10.1016/j.cell.2013.12.012 24439368 
10. Bergmann K.  Sypniewska G.   Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin. Chem. Lab. Med. 2013 51 177 185 10.1515/cclm-2012-0490 23241684 
11. Flier J.S.  Maratos-Flier E.   Lasker lauds leptin Cell 2010 143 9 12 10.1016/j.cell.2010.09.021 20887884 
12. Harvey J.  Solovyova N.  Irving A.   Leptin and its role in hippocampal synaptic plasticity Prog. Lipid Res. 2006 45 369 378 10.1016/j.plipres.2006.03.001 16678906 
13. De la Monte S.M.  Wands J.R.   Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer’s disease J. Alzheimers Dis. 2005 7 45 61 10.3233/JAD-2005-7106 15750214 
14. Steen E.  Terry B.M.  Rivera E.J.  Cannon J.L.  Neely T.R.  Tavares R.  Xu X.J.  Wands J.R.  de la Monte S.M.   Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—Is this type 3 diabetes? J. Alzheimers Dis. 2005 7 63 80 10.3233/JAD-2005-7107 15750215 
15. Schioth H.B.  Craft S.  Brooks S.J.  Frey W.H. 2nd  Benedict C.   Brain insulin signaling and Alzheimer’s disease: Current evidence and future directions Mol. Neurobiol. 2012 46 4 10 10.1007/s12035-011-8229-6 22205300 
16. Craft S.   Alzheimer disease: Insulin resistance and AD—Extending the translational path Nat. Rev. Neurol. 2012 8 360 362 10.1038/nrneurol.2012.112 22710630 
17. Ye R.  Scherer P.E.   Adiponectin, driver or passenger on the road to insulin sensitivity? Mol. Metab. 2013 2 133 141 10.1016/j.molmet.2013.04.001 24049728 
18. Maeda N.  Shimomura I.  Kishida K.  Nishizawa H.  Matsuda M.  Nagaretani H.  Furuyama N.  Kondo H.  Takahashi M.  Arita Y.    Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat. Med. 2002 8 731 737 10.1038/nm724 12068289 
19. Ng R.C.  Cheng O.Y.  Jian M.  Kwan J.S.  Ho P.W.  Cheng K.K.  Yeung P.K.  Zhou L.L.  Hoo R.L.  Chung S.K.    Chronic adiponectin deficiency leads to Alzheimer’s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice Mol. Neurodegener. 2016 11 71 10.1186/s13024-016-0136-x 27884163 
20. Yaffe K.   Metabolic syndrome and cognitive decline Curr. Alzheimer Res. 2007 4 123 126 10.2174/156720507780362191 17430234 
21. Biessels G.J.  Despa F.   Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications Nat. Rev. Endocrinol. 2018 14 591 604 10.1038/s41574-018-0048-7 30022099 
22. Stoeckel L.E.  Arvanitakis Z.  Gandy S.  Small D.  Kahn C.R.  Pascual-Leone A.  Sherwin R.  Smith P.   Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction F1000Research 2016 5 353 10.12688/f1000research.8300.2 27303627 
23. Gustafson D.   Adiposity indices and dementia Lancet Neurol. 2006 5 713 720 10.1016/S1474-4422(06)70526-9 16857578 
24. Garza J.C.  Guo M.  Zhang W.  Lu X.Y.   Leptin increases adult hippocampal neurogenesis in vivo and in vitro J. Biol. Chem. 2008 283 18238 18247 10.1074/jbc.M800053200 18367451 
25. Yau S.Y.  Li A.  Hoo R.L.  Ching Y.P.  Christie B.R.  Lee T.M.  Xu A.  So K.F.   Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin Proc. Natl. Acad. Sci. USA 2014 111 15810 15815 10.1073/pnas.1415219111 25331877 
26. Guo Z.  Jiang H.  Xu X.  Duan W.  Mattson M.P.   Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization J. Biol. Chem. 2008 283 1754 1763 10.1074/jbc.M703753200 17993459 
27. Song J.  Kang S.M.  Kim E.  Kim C.H.  Song H.T.  Lee J.E.   Adiponectin receptor-mediated signaling ameliorates cerebral cell damage and regulates the neurogenesis of neural stem cells at high glucose concentrations: An in vivo and in vitro study Cell Death Dis. 2015 6 e1844 10.1038/cddis.2015.220 26247729 
28. Formolo D.A.  Lee T.H.  Yau S.Y.   Increasing adiponergic system activity as a potential treatment for depressive disorders Mol. Neurobiol. 2019 10.1007/s12035-019-01644-3 31140056 
29. Huang S.  Wang Y.  Gan X.  Fang D.  Zhong C.  Wu L.  Hu G.  Sosunov A.A.  McKhann G.M.  Yu H.    Drp1-mediated mitochondrial abnormalities link to synaptic injury in diabetes model Diabetes 2015 64 1728 1742 10.2337/db14-0758 25412623 
30. Wang B.  Guo H.  Li X.  Yue L.  Liu H.  Zhao L.  Bai H.  Liu X.  Wu X.  Qu Y.   Adiponectin attenuates oxygen-glucose deprivation-induced mitochondrial oxidative injury and apoptosis in hippocampal HT22 cells via the JAK2/STAT3 pathway Cell Transpl. 2018 27 1731 1743 10.1177/0963689718779364 29947255 
31. Qiu G.  Wan R.  Hu J.  Mattson M.P.  Spangler E.  Liu S.  Yau S.Y.  Lee T.M.  Gleichmann M.  Ingram D.K.    Adiponectin protects rat hippocampal neurons against excitotoxicity Age 2011 33 155 165 10.1007/s11357-010-9173-5 20842535 
32. Song J.  Choi S.M.  Whitcomb D.J.  Kim B.C.   Adiponectin controls the apoptosis and the expression of tight junction proteins in brain endothelial cells through AdipoR1 under beta amyloid toxicity Cell Death Dis. 2017 8 e3102 10.1038/cddis.2017.491 29022894 
33. Nicolas S.  Cazareth J.  Zarif H.  Guyon A.  Heurteaux C.  Chabry J.  Petit-Paitel A.   Globular adiponectin limits microglia pro-inflammatory phenotype through an AdipoR1/NF-kappaB signaling pathway Front. Cell Neurosci. 2017 11 352 10.3389/fncel.2017.00352 29184485 
34. Zuloaga K.L.  Johnson L.A.  Roese N.E.  Marzulla T.  Zhang W.  Nie X.  Alkayed F.N.  Hong C.  Grafe M.R.  Pike M.M.    High fat diet-induced diabetes in mice exacerbates cognitive deficit due to chronic hypoperfusion J. Cereb. Blood Flow Metab. 2016 36 1257 1270 10.1177/0271678X15616400 26661233 
35. Li Z.  Hao S.  Yin H.  Gao J.  Yang Z.   Autophagy ameliorates cognitive impairment through activation of PVT1 and apoptosis in diabetes mice Behav. Brain Res. 2016 305 265 277 10.1016/j.bbr.2016.03.023 26971628 
36. Yan S.  Du F.  Wu L.  Zhang Z.  Zhong C.  Yu Q.  Wang Y.  Lue L.F.  Walker D.G.  Douglas J.T.    F1F0 ATP synthase-cyclophilin D interaction contributes to diabetes-induced synaptic dysfunction and cognitive decline Diabetes 2016 65 3482 3494 10.2337/db16-0556 27554467 
37. Kong F.J.  Wu J.H.  Sun S.Y.  Ma L.L.  Zhou J.Q.   Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes Neuropharmacology 2018 131 316 325 10.1016/j.neuropharm.2018.01.001 29305122 
38. Wang K.  Song F.  Xu K.  Liu Z.  Han S.  Li F.  Sun Y.   Irisin attenuates neuroinflammation and prevents the memory and cognitive deterioration in streptozotocin-induced diabetic mice Mediators Inflamm. 2019 2019 1567179 10.1155/2019/1567179 31281225 
39. Saravia F.E.  Beauquis J.  Revsin Y.  Homo-Delarche F.  de Kloet E.R.  De Nicola A.F.   Hippocampal neuropathology of diabetes mellitus is relieved by estrogen treatment Cell Mol. Neurobiol. 2006 26 943 957 10.1007/s10571-006-9096-y 16807785 
40. Li J.  Deng J.  Sheng W.  Zuo Z.   Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice Pharmacol. Biochem. Behav. 2012 101 564 574 10.1016/j.pbb.2012.03.002 22425595 
41. Hayashi-Park E.  Ozment B.N.  Griffith C.M.  Zhang H.  Patrylo P.R.  Rose G.M.   Experimentally induced diabetes worsens neuropathology, but not learning and memory, in middle aged 3xTg mice Behav. Brain Res. 2017 322 280 287 10.1016/j.bbr.2016.05.020 27173425 
42. Leuner B.  Gould E.   Structural plasticity and hippocampal function Annu. Rev. Psychol. 2010 61 111 140 10.1146/annurev.psych.093008.100359 19575621 
43. Brunner L.  Nick H.P.  Cumin F.  Chiesi M.  Baum H.P.  Whitebread S.  Stricker-Krongrad A.  Levens N.   Leptin is a physiologically important regulator of food intake Int. J. Obes. Relat. Metab. Disord. 1997 21 1152 1160 10.1038/sj.ijo.0800529 9426383 
44. Considine R.V.  Sinha M.K.  Heiman M.L.  Kriauciunas A.  Stephens T.W.  Nyce M.R.  Ohannesian J.P.  Marco C.C.  McKee L.J.  Bauer T.L.    Serum immunoreactive-leptin concentrations in normal-weight and obese humans N. Engl. J. Med. 1996 334 292 295 10.1056/NEJM199602013340503 8532024 
45. Licinio J.  Mantzoros C.  Negrao A.B.  Cizza G.  Wong M.L.  Bongiorno P.B.  Chrousos G.P.  Karp B.  Allen C.  Flier J.S.    Human leptin levels are pulsatile and inversely related to pituitary-adrenal function Nat. Med. 1997 3 575 579 10.1038/nm0597-575 9142131 
46. Sinha M.K.  Ohannesian J.P.  Heiman M.L.  Kriauciunas A.  Stephens T.W.  Magosin S.  Marco C.  Caro J.F.   Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects J. Clin. Investig. 1996 97 1344 1347 10.1172/JCI118551 8636448 
47. Boden G.  Chen X.  Mozzoli M.  Ryan I.   Effect of fasting on serum leptin in normal human subjects J. Clin. Endocrinol. Metab. 1996 81 3419 3423 8784108 
48. Chan J.L.  Heist K.  DePaoli A.M.  Veldhuis J.D.  Mantzoros C.S.   The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men J. Clin. Investig. 2003 111 1409 1421 10.1172/JCI200317490 12727933 
49. Chan J.L.  Mantzoros C.S.   Role of leptin in energy-deprivation states: Normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa Lancet 2005 366 74 85 10.1016/S0140-6736(05)66830-4 15993236 
50. Myers M.G.  Cowley M.A.  Munzberg H.   Mechanisms of leptin action and leptin resistance Annu. Rev. Physiol. 2008 70 537 556 10.1146/annurev.physiol.70.113006.100707 17937601 
51. Fischer S.  Hanefeld M.  Haffner S.M.  Fusch C.  Schwanebeck U.  Kohler C.  Fucker K.  Julius U.   Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass Acta Diabetol. 2002 39 105 110 10.1007/s005920200027 12357293 
52. Harris R.B.  Zhou J.  Redmann S.M. Jr.  Smagin G.N.  Smith S.R.  Rodgers E.  Zachwieja J.J.   A leptin dose-response study in obese (ob/ob) and lean (+/?) mice Endocrinology 1998 139 8 19 10.1210/endo.139.1.5675 9421392 
53. Berglund E.D.  Vianna C.R.  Donato J. Jr.  Kim M.H.  Chuang J.C.  Lee C.E.  Lauzon D.A.  Lin P.  Brule L.J.  Scott M.M.    Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice J. Clin. Investig. 2012 122 1000 1009 10.1172/JCI59816 22326958 
54. Cummings B.P.  Bettaieb A.  Graham J.L.  Stanhope K.L.  Dill R.  Morton G.J.  Haj F.G.  Havel P.J.   Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats Proc. Natl. Acad. Sci. USA 2011 108 14670 14675 10.1073/pnas.1107163108 21873226 
55. Morton G.J.  Gelling R.W.  Niswender K.D.  Morrison C.D.  Rhodes C.J.  Schwartz M.W.   Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons Cell Metab. 2005 2 411 420 10.1016/j.cmet.2005.10.009 16330326 
56. Coppari R.  Ichinose M.  Lee C.E.  Pullen A.E.  Kenny C.D.  McGovern R.A.  Tang V.  Liu S.M.  Ludwig T.  Chua S.C. Jr.    The hypothalamic arcuate nucleus: A key site for mediating leptin’s effects on glucose homeostasis and locomotor activity Cell Metab. 2005 1 63 72 10.1016/j.cmet.2004.12.004 16054045 
57. Enriori P.J.  Evans A.E.  Sinnayah P.  Jobst E.E.  Tonelli-Lemos L.  Billes S.K.  Glavas M.M.  Grayson B.E.  Perello M.  Nillni E.A.    Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons Cell Metab. 2007 5 181 194 10.1016/j.cmet.2007.02.004 17339026 
58. El-Haschimi K.  Pierroz D.D.  Hileman S.M.  Bjorbaek C.  Flier J.S.   Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity J. Clin. Investig. 2000 105 1827 1832 10.1172/JCI9842 10862798 
59. Munzberg H.  Flier J.S.  Bjorbaek C.   Region-specific leptin resistance within the hypothalamus of diet-induced obese mice Endocrinology 2004 145 4880 4889 10.1210/en.2004-0726 15271881 
60. Lin S.  Thomas T.C.  Storlien L.H.  Huang X.F.   Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice Int. J. Obes. Relat. Metab. Disord. 2000 24 639 646 10.1038/sj.ijo.0801209 10849588 
61. Mittendorfer B.  Horowitz J.F.  DePaoli A.M.  McCamish M.A.  Patterson B.W.  Klein S.   Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes Diabetes 2011 60 1474 1477 10.2337/db10-1302 21411512 
62. Moon H.S.  Matarese G.  Brennan A.M.  Chamberland J.P.  Liu X.  Fiorenza C.G.  Mylvaganam G.H.  Abanni L.  Carbone F.  Williams C.J.    Efficacy of metreleptin in obese patients with type 2 diabetes: Cellular and molecular pathways underlying leptin tolerance Diabetes 2011 60 1647 1656 10.2337/db10-1791 21617185 
63. Funahashi H.  Yada T.  Suzuki R.  Shioda S.   Distribution, function, and properties of leptin receptors in the brain Int. Rev. Cytol. 2003 224 1 27 12722947 
64. Zhou Y.  Rui L.   Leptin signaling and leptin resistance Front. Med. 2013 7 207 222 10.1007/s11684-013-0263-5 23580174 
65. Morrison C.D.   Leptin signaling in brain: A link between nutrition and cognition? Biochim. Biophys. Acta 2009 1792 401 408 10.1016/j.bbadis.2008.12.004 19130879 
66. Farr O.M.  Tsoukas M.A.  Mantzoros C.S.   Leptin and the brain: Influences on brain development, cognitive functioning and psychiatric disorders Metabolism 2015 64 114 130 10.1016/j.metabol.2014.07.004 25092133 
67. Coll A.P.  Farooqi I.S.  O’Rahilly S.   The hormonal control of food intake Cell 2007 129 251 262 10.1016/j.cell.2007.04.001 17448988 
68. Ahima R.S.  Prabakaran D.  Mantzoros C.  Qu D.  Lowell B.  Maratos-Flier E.  Flier J.S.   Role of leptin in the neuroendocrine response to fasting Nature 1996 382 250 252 10.1038/382250a0 8717038 
69. Cristino L.  Busetto G.  Imperatore R.  Ferrandino I.  Palomba L.  Silvestri C.  Petrosino S.  Orlando P.  Bentivoglio M.  Mackie K.    Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons Proc. Natl. Acad. Sci. USA 2013 110 E2229 E2238 10.1073/pnas.1219485110 23630288 
70. Cason A.M.  Smith R.J.  Tahsili-Fahadan P.  Moorman D.E.  Sartor G.C.  Aston-Jones G.   Role of orexin/hypocretin in reward-seeking and addiction: Implications for obesity Physiol. Behav. 2010 100 419 428 10.1016/j.physbeh.2010.03.009 20338186 
71. Hay-Schmidt A.  Helboe L.  Larsen P.J.   Leptin receptor immunoreactivity is present in ascending serotonergic and catecholaminergic neurons of the rat Neuroendocrinology 2001 73 215 226 10.1159/000054638 11340335 
72. Figlewicz D.P.  Evans S.B.  Murphy J.  Hoen M.  Baskin D.G.   Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat Brain Res. 2003 964 107 115 10.1016/S0006-8993(02)04087-8 12573518 
73. Balland E.  Cowley M.A.   New insights in leptin resistance mechanisms in mice Front. Neuroendocrinol. 2015 39 59 65 10.1016/j.yfrne.2015.09.004 26410445 
74. Hara J.  Beuckmann C.T.  Nambu T.  Willie J.T.  Chemelli R.M.  Sinton C.M.  Sugiyama F.  Yagami K.  Goto K.  Yanagisawa M.    Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity Neuron 2001 30 345 354 10.1016/S0896-6273(01)00293-8 11394998 
75. Harris G.C.  Wimmer M.  Aston-Jones G.   A role for lateral hypothalamic orexin neurons in reward seeking Nature 2005 437 556 559 10.1038/nature04071 16100511 
76. Narita M.  Nagumo Y.  Hashimoto S.  Narita M.  Khotib J.  Miyatake M.  Sakurai T.  Yanagisawa M.  Nakamachi T.  Shioda S.    Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine J. Neurosci. 2006 26 398 405 10.1523/JNEUROSCI.2761-05.2006 16407535 
77. Liu J.J.  Bello N.T.  Pang Z.P.   Presynaptic regulation of leptin in a defined lateral hypothalamus-ventral tegmental area neurocircuitry depends on energy state J. Neurosci. 2017 37 11854 11866 10.1523/JNEUROSCI.1942-17.2017 29089444 
78. Salamone J.D.  Correa M.  Mingote S.M.  Weber S.M.   Beyond the reward hypothesis: Alternative functions of nucleus accumbens dopamine Curr. Opin. Pharmacol. 2005 5 34 41 10.1016/j.coph.2004.09.004 15661623 
79. Kelley A.E.  Baldo B.A.  Pratt W.E.  Will M.J.   Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and reward Physiol. Behav. 2005 86 773 795 10.1016/j.physbeh.2005.08.066 16289609 
80. Schultz W.   Behavioral dopamine signals Trends Neurosci. 2007 30 203 210 10.1016/j.tins.2007.03.007 17400301 
81. Coccurello R.  Maccarrone M.   Hedonic eating and the “Delicious circle”: From lipid-derived mediators to brain dopamine and back Front. Neurosci. 2018 12 271 10.3389/fnins.2018.00271 29740277 
82. Leinninger G.M.  Jo Y.H.  Leshan R.L.  Louis G.W.  Yang H.  Barrera J.G.  Wilson H.  Opland D.M.  Faouzi M.A.  Gong Y.    Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding Cell Metab. 2009 10 89 98 10.1016/j.cmet.2009.06.011 19656487 
83. Davis J.F.  Choi D.L.  Schurdak J.D.  Fitzgerald M.F.  Clegg D.J.  Lipton J.W.  Figlewicz D.P.  Benoit S.C.   Leptin regulates energy balance and motivation through action at distinct neural circuits Biol. Psychiatry 2011 69 668 674 10.1016/j.biopsych.2010.08.028 21035790 
84. Fulton S.  Pissios P.  Manchon R.P.  Stiles L.  Frank L.  Pothos E.N.  Maratos-Flier E.  Flier J.S.   Leptin regulation of the mesoaccumbens dopamine pathway Neuron 2006 51 811 822 10.1016/j.neuron.2006.09.006 16982425 
85. Korotkova T.M.  Brown R.E.  Sergeeva O.A.  Ponomarenko A.A.  Haas H.L.   Effects of arousal- and feeding-related neuropeptides on dopaminergic and GABAergic neurons in the ventral tegmental area of the rat Eur. J. Neurosci. 2006 23 2677 2685 10.1111/j.1460-9568.2006.04792.x 16817870 
86. Krugel U.  Schraft T.  Kittner H.  Kiess W.  Illes P.   Basal and feeding-evoked dopamine release in the rat nucleus accumbens is depressed by leptin Eur. J. Pharmacol. 2003 482 185 187 10.1016/j.ejphar.2003.09.047 14660021 
87. Morton G.J.  Blevins J.E.  Kim F.  Matsen M.  Figlewicz D.P.   The action of leptin in the ventral tegmental area to decrease food intake is dependent on Jak-2 signaling Am. J. Physiol. Endocrinol. Metab. 2009 297 E202 E210 10.1152/ajpendo.90865.2008 19435852 
88. Scarpace P.J.  Matheny M.  Kirichenko N.  Gao Y.X.  Tumer N.  Zhang Y.   Leptin overexpression in VTA trans-activates the hypothalamus whereas prolonged leptin action in either region cross-desensitizes Neuropharmacology 2013 65 90 100 10.1016/j.neuropharm.2012.09.005 22982569 
89. Hommel J.D.  Trinko R.  Sears R.M.  Georgescu D.  Liu Z.W.  Gao X.B.  Thurmon J.J.  Marinelli M.  DiLeone R.J.   Leptin receptor signaling in midbrain dopamine neurons regulates feeding Neuron 2006 51 801 810 10.1016/j.neuron.2006.08.023 16982424 
90. Shen M.  Jiang C.  Liu P.  Wang F.  Ma L.   Mesolimbic leptin signaling negatively regulates cocaine-conditioned reward Transl. Psychiatry 2016 6 e972 10.1038/tp.2016.223 27922639 
91. Haass-Koffler C.L.  Aoun E.G.  Swift R.M.  de la Monte S.M.  Kenna G.A.  Leggio L.   Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving Transl. Psychiatry 2015 5 e646 10.1038/tp.2015.140 26418274 
92. Maes M.  Bocchio Chiavetto L.  Bignotti S.  Battisa Tura G.  Pioli R.  Boin F.  Kenis G.  Bosmans E.  de Jongh R.  Lin A.    Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics Eur. Neuropsychopharmacol. 2000 10 119 124 10.1016/S0924-977X(99)00062-0 10706993 
93. Coccurello R.  Moles A.   Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design Pharmacol. Ther. 2010 127 210 251 10.1016/j.pharmthera.2010.04.008 20493213 
94. Sapra M.  Lawson D.  Iranmanesh A.  Varma A.   Adiposity-independent hypoadiponectinemia as a potential marker of insulin resistance and inflammation in schizophrenia patients treated with second generation antipsychotics Schizophr. Res. 2016 174 132 136 10.1016/j.schres.2016.04.051 27211515 
95. Flowers S.A.  Evans S.J.  Ward K.M.  McInnis M.G.  Ellingrod V.L.   Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort Pharmacotherapy 2017 37 261 267 10.1002/phar.1890 28035686 
96. Chen J.  Huang X.F.  Shao R.  Chen C.  Deng C.   Molecular mechanisms of antipsychotic drug-induced diabetes Front. Neurosci. 2017 11 643 10.3389/fnins.2017.00643 29209160 
97. Singh R.  Bansal Y.  Medhi B.  Kuhad A.   Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives Eur. J. Pharmacol. 2019 844 231 240 10.1016/j.ejphar.2018.12.003 30529195 
98. Xu H.  Zhuang X.   Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: A critical review Neuropsychiatr. Dis. Treat. 2019 15 2087 2099 10.2147/NDT.S208061 31413575 
99. Kraus T.  Haack M.  Schuld A.  Hinze-Selch D.  Kühn M.  Uhr M.  Pollmächer T.   Body weight and leptin plasma levels during treatment with antipsychotic drugs Am. J. Psychiatry 1999 156 312 314 9989571 
100. McIntyre R.S.  Mancini D.A.  Basile V.S.  Srinivasan J.  Kennedy S.H.   Antipsychotic-induced weight gain: Bipolar disorder and leptin J. Clin. Psychopharmacol. 2003 23 323 327 10.1097/01.jcp.0000085403.08426.f4 12920406 
101. Popovic V.  Doknic M.  Maric N.  Pekic S.  Damjanovic A.  Miljic D.  Popovic S.  Miljic N.  Djurovic M.  Jasovic-Gasic M.    Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia Neuroendocrinology 2007 85 249 256 10.1159/000103868 17570902 
102. Potvin S.  Zhornitsky S.  Stip E.   Antipsychotic-induced changes in blood levels of leptin in schizophrenia: A meta-analysis Can. J. Psychiatry 2015 60 Suppl. 2 S26 S34 25886677 
103. Ota M.  Mori K.  Nakashima A.  Kaneko Y.S.  Fujiwara K.  Itoh M.  Nagasaka A.  Ota A.   Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats Clin. Exp. Pharmacol. Physiol. 2002 29 980 989 10.1046/j.1440-1681.2002.t01-1-03755.x 12366389 
104. Albaugh V.L.  Henry C.R.  Bello N.T.  Hajnal A.  Lynch S.L.  Halle B.  Lynch C.J.   Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents Obesity 2006 14 36 51 10.1038/oby.2006.6 16493121 
105. Minet-Ringuet J.  Even P.C.  Goubern M.  Tome D.  de Beaurepaire R.   Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration Appetite 2006 46 254 262 10.1016/j.appet.2006.01.008 16551485 
106. Minet-Ringuet J.  Even P.C.  Lacroix M.  Tome D.  de Beaurepaire R.   A model for antipsychotic-induced obesity in the male rat Psychopharmacology 2006 187 447 454 10.1007/s00213-006-0433-0 16783538 
107. Lord C.C.  Wyler S.C.  Wan R.  Castorena C.M.  Ahmed N.  Mathew D.  Lee S.  Liu C.  Elmquist J.K.   The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor, 2C J. Clin. Investig. 2017 127 3402 3406 10.1172/JCI93362 28805659 
108. Kusumi I.  Boku S.  Takahashi Y.   Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis Psychiatry Clin. Neurosci. 2015 69 243 258 10.1111/pcn.12242 25296946 
109. Meltzer H.Y.   What’s atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 2004 4 53 57 10.1016/j.coph.2003.09.010 15018839 
110. Basile V.S.  Masellis M.  McIntyre R.S.  Meltzer H.Y.  Lieberman J.A.  Kennedy J.L.   Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle J. Clin. Psychiatry 2001 62 Suppl. 23 45 66 11603885 
111. Starrenburg F.C.  Bogers J.P.   How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins Eur. Psychiatry 2009 24 164 170 10.1016/j.eurpsy.2009.01.001 19285836 
112. Gettys T.W.  Harkness P.J.  Watson P.M.   The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes Endocrinology 1996 137 4054 4057 10.1210/endo.137.9.8756584 8756584 
113. Munzberg H.   Differential leptin access into the brain—A hierarchical organization of hypothalamic leptin target sites? Physiol. Behav. 2008 94 664 669 10.1016/j.physbeh.2008.04.020 18502454 
114. Morash B.  Li A.  Murphy P.R.  Wilkinson M.  Ur E.   Leptin gene expression in the brain and pituitary gland Endocrinology 1999 140 5995 5998 10.1210/endo.140.12.7288 10579368 
115. Ur E.  Wilkinson D.A.  Morash B.A.  Wilkinson M.   Leptin immunoreactivity is localized to neurons in rat brain Neuroendocrinology 2002 75 264 272 10.1159/000054718 11979057 
116. Banks W.A.  Clever C.M.  Farrell C.L.   Partial saturation and regional variation in the blood-to-brain transport of leptin in normal weight mice Am. J. Physiol. Endocrinol. Metab. 2000 278 E1158 E1165 10.1152/ajpendo.2000.278.6.E1158 10827020 
117. Van Doorn C.  Macht V.A.  Grillo C.A.  Reagan L.P.   Leptin resistance and hippocampal behavioral deficits Physiol. Behav. 2017 176 207 213 10.1016/j.physbeh.2017.03.002 28267584 
118. Stranahan A.M.  Arumugam T.V.  Cutler R.G.  Lee K.  Egan J.M.  Mattson M.P.   Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons Nat. Neurosci. 2008 11 309 317 10.1038/nn2055 18278039 
119. Dhar M.  Zhu M.  Impey S.  Lambert T.J.  Bland T.  Karatsoreos I.N.  Nakazawa T.  Appleyard S.M.  Wayman G.A.   Leptin induces hippocampal synaptogenesis via CREB-regulated microRNA-132 suppression of, p.2.5.0.G.A.P Mol. Endocrinol. 2014 28 1073 1087 10.1210/me.2013-1332 24877561 
120. Li X.L.  Aou S.  Oomura Y.  Hori N.  Fukunaga K.  Hori T.   Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents Neuroscience 2002 113 607 615 10.1016/S0306-4522(02)00162-8 12150780 
121. Gerges N.Z.  Aleisa A.M.  Alkadhi K.A.   Impaired long-term potentiation in obese zucker rats: Possible involvement of presynaptic mechanism Neuroscience 2003 120 535 539 10.1016/S0306-4522(03)00297-5 12890522 
122. Guo M.  Lu Y.  Garza J.C.  Li Y.  Chua S.C.  Zhang W.  Lu B.  Lu X.Y.   Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression Transl. Psychiatry 2012 2 e83 10.1038/tp.2012.9 22408745 
123. Koch C.E.  Lowe C.  Pretz D.  Steger J.  Williams L.M.  Tups A.   High-fat diet induces leptin resistance in leptin-deficient mice J. Neuroendocrinol. 2014 26 58 67 10.1111/jne.12131 24382295 
124. Wang B.  Chandrasekera P.C.  Pippin J.J.   Leptin- and leptin receptor-deficient rodent models: Relevance for human type 2 diabetes Curr. Diabetes Rev. 2014 10 131 145 10.2174/1573399810666140508121012 24809394 
125. O’Malley D.  MacDonald N.  Mizielinska S.  Connolly C.N.  Irving A.J.  Harvey J.   Leptin promotes rapid dynamic changes in hippocampal dendritic morphology Mol. Cell. Neurosci. 2007 35 559 572 10.1016/j.mcn.2007.05.001 17618127 
126. Liu J.  Garza J.C.  Bronner J.  Kim C.S.  Zhang W.  Lu X.Y.   Acute administration of leptin produces anxiolytic-like effects: A comparison with fluoxetine Psychopharmacology 2010 207 535 545 10.1007/s00213-009-1684-3 19823809 
127. Farr S.A.  Banks W.A.  Morley J.E.   Effects of leptin on memory processing Peptides 2006 27 1420 1425 10.1016/j.peptides.2005.10.006 16293343 
128. Kanoski S.E.  Hayes M.R.  Greenwald H.S.  Fortin S.M.  Gianessi C.A.  Gilbert J.R.  Grill H.J.   Hippocampal leptin signaling reduces food intake and modulates food-related memory processing Neuropsychopharmacology 2011 36 1859 1870 10.1038/npp.2011.70 21544068 
129. Suarez A.N.  Noble E.E.  Kanoski S.E.   Regulation of memory function by feeding-relevant biological systems: following the breadcrumbs to the hippocampus Front. Mol. Neurosci. 2019 12 101 10.3389/fnmol.2019.00101 31057368 
130. Bliss T.V.  Collingridge G.L.   A synaptic model of memory: Long-term potentiation in the hippocampus Nature 1993 361 31 39 10.1038/361031a0 8421494 
131. Wayner M.J.  Armstrong D.L.  Phelix C.F.  Oomura Y.   Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo Peptides 2004 25 991 996 10.1016/j.peptides.2004.03.018 15203246 
132. Malenka R.C.   Postsynaptic factors control the duration of synaptic enhancement in area CA1 of the hippocampus Neuron 1991 6 53 60 10.1016/0896-6273(91)90121-F 1670922 
133. Greco S.J.  Bryan K.J.  Sarkar S.  Zhu X.  Smith M.A.  Ashford J.W.  Johnston J.M.  Tezapsidis N.  Casadesus G.   Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer’s disease J. Alzheimers Dis. 2010 19 1155 1167 10.3233/JAD-2010-1308 20308782 
134. Tong J.Q.  Zhang J.  Hao M.  Yang J.  Han Y.F.  Liu X.J.  Shi H.  Wu M.N.  Liu Q.S.  Qi J.S.   Leptin attenuates the detrimental effects of beta-amyloid on spatial memory and hippocampal later-phase long term potentiation in rats Horm. Behav. 2015 73 125 130 10.1016/j.yhbeh.2015.06.013 26135065 
135. Liu Z.  Zhang Y.  Liu J.  Yin F.   Geniposide attenuates the level of Aβ1-42 via enhancing leptin signaling in cellular and APP/PS1 transgenic mice Arch. Pharmacal Res. 2017 40 571 578 10.1007/s12272-016-0875-9 28160136 
136. Yamamoto N.  Tanida M.  Kasahara R.  Sobue K.  Suzuki K.   Leptin inhibits amyloid beta-protein fibrillogenesis by decreasing GM1 gangliosides on the neuronal cell surface through PI3K/Akt/mTOR pathway J. Neurochem. 2014 131 323 332 10.1111/jnc.12828 25039425 
137. Chandran M.  Phillips S.A.  Ciaraldi T.  Henry R.R.   Adiponectin: More than just another fat cell hormone? Diabetes Care 2003 26 2442 2450 10.2337/diacare.26.8.2442 12882876 
138. Kawano J.  Arora R.   The role of adiponectin in obesity, diabetes, and cardiovascular disease J. Cardiometab. Syndr. 2009 4 44 49 10.1111/j.1559-4572.2008.00030.x 19245516 
139. Yamauchi T.  Kamon J.  Ito Y.  Tsuchida A.  Yokomizo T.  Kita S.  Sugiyama T.  Miyagishi M.  Hara K.  Tsunoda M.    Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 2003 423 762 769 10.1038/nature01705 12802337 
140. Arita Y.  Kihara S.  Ouchi N.  Takahashi M.  Maeda K.  Miyagawa J.  Hotta K.  Shimomura I.  Nakamura T.  Miyaoka K.    Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity Biochem. Biophys. Res. Commun. 1999 257 79 83 10.1006/bbrc.1999.0255 10092513 
141. Hotta K.  Funahashi T.  Arita Y.  Takahashi M.  Matsuda M.  Okamoto Y.  Iwahashi H.  Kuriyama H.  Ouchi N.  Maeda K.    Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients Arterioscler. Thromb. Vasc. Biol. 2000 20 1595 1599 10.1161/01.ATV.20.6.1595 10845877 
142. Guenther M.  James R.  Marks J.  Zhao S.  Szabo A.  Kidambi S.   Adiposity distribution influences circulating adiponectin levels Transl. Res. 2014 164 270 277 10.1016/j.trsl.2014.04.008 24811003 
143. Kim J.Y.  van de Wall E.  Laplante M.  Azzara A.  Trujillo M.E.  Hofmann S.M.  Schraw T.  Durand J.L.  Li H.  Li G.    Obesity-associated improvements in metabolic profile through expansion of adipose tissue J. Clin. Investig. 2007 117 2621 2637 10.1172/JCI31021 17717599 
144. Guo C.  Ricchiuti V.  Lian B.Q.  Yao T.M.  Coutinho P.  Romero J.R.  Li J.  Williams G.H.  Adler G.K.   Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines Circulation 2008 117 2253 2261 10.1161/CIRCULATIONAHA.107.748640 18427128 
145. Saleh S.  El-Maraghy N.  Reda E.  Barakat W.   Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: Role of adiponectin and TNF-alpha An. Acad. Bras. Cienc. 2014 86 1935 1948 10.1590/0001-3765201420140212 25590730 
146. Croze M.L.  Geloen A.  Soulage C.O.   Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: Benefits of a dietary myo-inositol supplementation Br. J. Nutr. 2015 113 1862 1875 10.1017/S000711451500121X 25990651 
147. Holmes R.M.  Yi Z.  De Filippis E.  Berria R.  Shahani S.  Sathyanarayana P.  Sherman V.  Fujiwara K.  Meyer C.  Christ-Roberts C.    Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: Evidence for altered adiponectin signalling Diabetologia 2011 54 2122 2131 10.1007/s00125-011-2173-x 21562756 
148. Felder T.K.  Hahne P.  Soyal S.M.  Miller K.  Hoffinger H.  Oberkofler H.  Krempler F.  Patsch W.   Hepatic adiponectin receptors (ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in obese humans Int. J. Obes. 2010 34 846 851 10.1038/ijo.2010.7 20125105 
149. Okamoto Y.  Folco E.J.  Minami M.  Wara A.K.  Feinberg M.W.  Sukhova G.K.  Colvin R.A.  Kihara S.  Funahashi T.  Luster A.D.    Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis Circ. Res. 2008 102 218 225 10.1161/CIRCRESAHA.107.164988 17991878 
150. Yang W.S.  Jeng C.Y.  Wu T.J.  Tanaka S.  Funahashi T.  Matsuzawa Y.  Wang J.P.  Chen C.L.  Tai T.Y.  Chuang L.M.   Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients Diabetes Care 2002 25 376 380 10.2337/diacare.25.2.376 11815513 
151. Fry M.  Smith P.M.  Hoyda T.D.  Duncan M.  Ahima R.S.  Sharkey K.A.  Ferguson A.V.   Area postrema neurons are modulated by the adipocyte hormone adiponectin J. Neurosci. 2006 26 9695 9702 10.1523/JNEUROSCI.2014-06.2006 16988040 
152. Hoyda T.D.  Fry M.  Ahima R.S.  Ferguson A.V.   Adiponectin selectively inhibits oxytocin neurons of the paraventricular nucleus of the hypothalamus J. Physiol. 2007 585 805 816 10.1113/jphysiol.2007.144519 17947308 
153. Neumeier M.  Weigert J.  Buettner R.  Wanninger J.  Schaffler A.  Muller A.M.  Killian S.  Sauerbruch S.  Schlachetzki F.  Steinbrecher A.    Detection of adiponectin in cerebrospinal fluid in humans Am. J. Physiol. Endocrinol. Metab. 2007 293 E965 E969 10.1152/ajpendo.00119.2007 17623750 
154. Rodriguez-Pacheco F.  Martinez-Fuentes A.J.  Tovar S.  Pinilla L.  Tena-Sempere M.  Dieguez C.  Castano J.P.  Malagon M.M.   Regulation of pituitary cell function by adiponectin Endocrinology 2007 148 401 410 10.1210/en.2006-1019 17038552 
155. Thundyil J.  Tang S.C.  Okun E.  Shah K.  Karamyan V.T.  Li Y.I.  Woodruff T.M.  Taylor S.M.  Jo D.G.  Mattson M.P.    Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death Exp. Transl. Stroke Med. 2010 2 15 10.1186/2040-7378-2-15 20701790 
156. Repunte-Canonigo V.  Berton F.  Cottone P.  Reifel-Miller A.  Roberts A.J.  Morales M.  Francesconi W.  Sanna P.P.   A potential role for adiponectin receptor 2 (AdipoR2) in the regulation of alcohol intake Brain Res. 2010 1339 11 17 10.1016/j.brainres.2010.03.060 20380822 
157. Zhang D.  Guo M.  Zhang W.  Lu X.Y.   Adiponectin stimulates proliferation of adult hippocampal neural stem/progenitor cells through activation of p38 mitogen-activated protein kinase (p38MAPK)/glycogen synthase kinase 3beta (GSK-3beta)/beta-catenin signaling cascade J. Biol. Chem. 2011 286 44913 44920 10.1074/jbc.M111.310052 22039048 
158. Liu J.  Guo M.  Zhang D.  Cheng S.Y.  Liu M.  Ding J.  Scherer P.E.  Liu F.  Lu X.Y.   Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity Proc. Natl. Acad. Sci. USA 2012 109 12248 12253 10.1073/pnas.1202835109 22778410 
159. Varhelyi Z.P.  Kalman J.  Olah Z.  Ivitz E.V.  Fodor E.K.  Santha M.  Datki Z.L.  Pakaski M.   Adiponectin receptors are less sensitive to stress in a transgenic mouse model of Alzheimer’s disease Front. Neurosci. 2017 11 199 10.3389/fnins.2017.00199 28442988 
160. Koch C.E.  Lowe C.  Legler K.  Benzler J.  Boucsein A.  Bottiger G.  Grattan D.R.  Williams L.M.  Tups A.   Central adiponectin acutely improves glucose tolerance in male mice Endocrinology 2014 155 1806 1816 10.1210/en.2013-1734 24564394 
161. Wang B.  Cheng K.K.   Hypothalamic AMPK as a mediator of hormonal regulation of energy balance Int. J. Mol. Sci. 2018 19 3552 10.3390/ijms19113552 30423881 
162. Kubota N.  Yano W.  Kubota T.  Yamauchi T.  Itoh S.  Kumagai H.  Kozono H.  Takamoto I.  Okamoto S.  Shiuchi T.    Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake Cell Metab. 2007 6 55 68 10.1016/j.cmet.2007.06.003 17618856 
163. Sun J.  Gao Y.  Yao T.  Huang Y.  He Z.  Kong X.  Yu K.J.  Wang R.T.  Guo H.  Yan J.    Adiponectin potentiates the acute effects of leptin in arcuate Pomc neurons Mol. Metab. 2016 5 882 891 10.1016/j.molmet.2016.08.007 27689001 
164. Qi Y.  Takahashi N.  Hileman S.M.  Patel H.R.  Berg A.H.  Pajvani U.B.  Scherer P.E.  Ahima R.S.   Adiponectin acts in the brain to decrease body weight Nat. Med. 2004 10 524 529 10.1038/nm1029 15077108 
165. Suyama S.  Maekawa F.  Maejima Y.  Kubota N.  Kadowaki T.  Yada T.   Glucose level determines excitatory or inhibitory effects of adiponectin on arcuate POMC neuron activity and feeding Sci. Rep. 2016 6 30796 10.1038/srep30796 27503800 
166. Suyama S.  Lei W.  Kubota N.  Kadowaki T.  Yada T.   Adiponectin at physiological level glucose-independently enhances inhibitory postsynaptic current onto NPY neurons in the hypothalamic arcuate nucleus Neuropeptides 2017 65 1 9 10.1016/j.npep.2017.03.003 28606559 
167. Hanssens L.  van Winkel R.  Wampers M.  Van Eyck D.  Scheen A.  Reginster J.Y.  Collette J.  Peuskens J.  De Hert M.   A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder Schizophr. Res. 2008 106 308 314 10.1016/j.schres.2008.09.008 18930377 
168. Bartoli F.  Crocamo C.  Clerici M.  Carra G.   Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis Eur. Neuropsychopharmacol. 2015 25 1767 1774 10.1016/j.euroneuro.2015.06.011 26164075 
169. De Hert M.  Schreurs V.  Sweers K.  Van Eyck D.  Hanssens L.  Sinko S.  Wampers M.  Scheen A.  Peuskens J.  van Winkel R.   Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review Schizophr. Res. 2008 101 295 303 10.1016/j.schres.2008.01.028 18299188 
170. Bai Y.M.  Chen T.T.  Yang W.S.  Chi Y.C.  Lin C.C.  Liou Y.J.  Wang Y.C.  Su T.P.  Chou P.  Chen J.Y.   Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study Schizophr. Res. 2009 111 1 8 10.1016/j.schres.2009.03.014 19409756 
171. Weston-Green K.  Huang X.F.  Deng C.   Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain PLoS ONE 2012 7 e33548 10.1371/journal.pone.0033548 22438946 
172. Murashita M.  Inoue T.  Kusumi I.  Nakagawa S.  Itoh K.  Tanaka T.  Izumi T.  Hosoda H.  Kangawa K.  Koyama T.   Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia Psychiatry Clin. Neurosci. 2007 61 54 58 10.1111/j.1440-1819.2007.01610.x 17239039 
173. Wampers M.  Hanssens L.  van Winkel R.  Heald A.  Collette J.  Peuskens J.  Reginster J.Y.  Scheen A.  De Hert M.   Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study Eur. Neuropsychopharmacol. 2012 22 17 26 10.1016/j.euroneuro.2011.03.010 21511441 
174. Bartoli F.  Lax A.  Crocamo C.  Clerici M.  Carra G.   Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: A meta-analysis Psychoneuroendocrinology 2015 56 179 189 10.1016/j.psyneuen.2015.03.012 25827962 
175. Sun F.  Lei Y.  You J.  Li C.  Sun L.  Garza J.  Zhang D.  Guo M.  Scherer P.E.  Lodge D.    Adiponectin modulates ventral tegmental area dopamine neuron activity and anxiety-related behavior through AdipoR1 Mol. Psychiatry 2019 24 126 144 10.1038/s41380-018-0102-9 29988086 
176. Nestler E.J.  Carlezon W.A. Jr.   The mesolimbic dopamine reward circuit in depression Biol. Psychiatry 2006 59 1151 1159 10.1016/j.biopsych.2005.09.018 16566899 
177. Coque L.  Mukherjee S.  Cao J.L.  Spencer S.  Marvin M.  Falcon E.  Sidor M.M.  Birnbaum S.G.  Graham A.  Neve R.L.    Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockDelta19 mouse model of mania Neuropsychopharmacology 2011 36 1478 1488 10.1038/npp.2011.33 21430648 
178. Tye K.M.  Mirzabekov J.J.  Warden M.R.  Ferenczi E.A.  Tsai H.C.  Finkelstein J.  Kim S.Y.  Adhikari A.  Thompson K.R.  Andalman A.S.    Dopamine neurons modulate neural encoding and expression of depression-related behaviour Nature 2013 493 537 541 10.1038/nature11740 23235822 
179. Chaudhury D.  Walsh J.J.  Friedman A.K.  Juarez B.  Ku S.M.  Koo J.W.  Ferguson D.  Tsai H.C.  Pomeranz L.  Christoffel D.J.    Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons Nature 2013 493 532 536 10.1038/nature11713 23235832 
180. Kahl K.G.  Schweiger U.  Correll C.  Muller C.  Busch M.L.  Bauer M.  Schwarz P.   Depression, anxiety disorders, and metabolic syndrome in a population at risk for type 2 diabetes mellitus Brain Behav. 2015 5 e00306 10.1002/brb3.306 25642391 
181. Turer A.T.  Khera A.  Ayers C.R.  Turer C.B.  Grundy S.M.  Vega G.L.  Scherer P.E.   Adipose tissue mass and location affect circulating adiponectin levels Diabetologia 2011 54 2515 2524 10.1007/s00125-011-2252-z 21779869 
182. Okamoto Y.  Kihara S.  Funahashi T.  Matsuzawa Y.  Libby P.   Adiponectin: A key adipocytokine in metabolic syndrome Clin. Sci. (Lond.) 2006 110 267 278 10.1042/CS20050182 16464169 
183. Garcia-Casares N.  Garcia-Arnes J.A.  Rioja J.  Ariza M.J.  Gutierrez A.  Alfaro F.  Nabrozidis A.  Gonzalez-Alegre P.  Gonzalez-Santos P.   Alzheimer’s like brain changes correlate with low adiponectin plasma levels in type 2 diabetic patients J. Diabetes Complicat. 2016 30 281 286 10.1016/j.jdiacomp.2015.12.001 26796431 
184. Teixeira A.L.  Diniz B.S.  Campos A.C.  Miranda A.S.  Rocha N.P.  Talib L.L.  Gattaz W.F.  Forlenza O.V.   Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer’s disease Neuromolecular. Med. 2013 15 115 121 10.1007/s12017-012-8201-2 23055000 
185. Zhang D.  Wang X.  Lu X.Y.   Adiponectin Exerts Neurotrophic Effects on Dendritic Arborization, Spinogenesis, and Neurogenesis of the Dentate Gyrus of Male Mice Endocrinology 2016 157 2853 2869 10.1210/en.2015-2078 27187175 
186. Kim M.W.  Abid N.B.  Jo M.H.  Jo M.G.  Yoon G.H.  Kim M.O.   Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer’s disease-like pathologies Sci. Rep. 2017 7 12435 10.1038/s41598-017-12632-9 28963462 
187. Nicolas S.  Veyssiere J.  Gandin C.  Zsurger N.  Pietri M.  Heurteaux C.  Glaichenhaus N.  Petit-Paitel A.  Chabry J.   Neurogenesis-independent antidepressant-like effects of enriched environment is dependent on adiponectin Psychoneuroendocrinology 2015 57 72 83 10.1016/j.psyneuen.2015.03.017 25889841 
188. Chabry J.  Nicolas S.  Cazareth J.  Murris E.  Guyon A.  Glaichenhaus N.  Heurteaux C.  Petit-Paitel A.   Enriched environment decreases microglia and brain macrophages inflammatory phenotypes through adiponectin-dependent mechanisms: Relevance to depressive-like behavior Brain Behav. Immun. 2015 50 275 287 10.1016/j.bbi.2015.07.018 26209808 
189. Guo M.  Li C.  Lei Y.  Xu S.  Zhao D.  Lu X.Y.   Role of the adipose PPARgamma-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors Mol. Psychiatry 2017 22 1056 1068 10.1038/mp.2016.225 27956741 
190. Yamaguchi N.  Argueta J.G.  Masuhiro Y.  Kagishita M.  Nonaka K.  Saito T.  Hanazawa S.  Yamashita Y.   Adiponectin inhibits Toll-like receptor family-induced signaling FEBS Lett. 2005 579 6821 6826 10.1016/j.febslet.2005.11.019 16325814 
191. Mandal P.  Pratt B.T.  Barnes M.  McMullen M.R.  Nagy L.E.   Molecular mechanism for adiponectin-dependent M2 macrophage polarization: Link between the metabolic and innate immune activity of full-length adiponectin J. Biol. Chem. 2011 286 13460 13469 10.1074/jbc.M110.204644 21357416 
192. Xu Z.P.  Gan G.S.  Liu Y.M.  Xiao J.S.  Liu H.X.  Mei B.  Zhang J.J.   Adiponectin Attenuates Streptozotocin-Induced Tau Hyperphosphorylation and Cognitive Deficits by Rescuing PI3K/Akt/GSK-3beta Pathway Neurochem. Res. 2018 43 316 323 10.1007/s11064-017-2426-2 29098530 
193. Jian M.  Kwan J.S.  Bunting M.  Ng R.C.  Chan K.H.   Adiponectin suppresses amyloid-beta oligomer (AbetaO)-induced inflammatory response of microglia via AdipoR1-AMPK-NF-kappaB signaling pathway J. Neuroinflamm. 2019 16 110 10.1186/s12974-019-1492-6 31128596 
194. Song J.  Choi S.M.  Kim B.C.   Adiponectin Regulates the Polarization and Function of Microglia via PPAR-gamma Signaling Under Amyloid beta Toxicity Front. Cell Neurosci. 2017 11 64 10.3389/fncel.2017.00064 28326017 
195. Wang M.  Jo J.  Song J.   Adiponectin improves long-term potentiation in the 5XFAD mouse brain Sci. Rep. 2019 9 8918 10.1038/s41598-019-45509-0 31222110 
196. Rourke J.L.  Dranse H.J.  Sinal C.J.   Towards an integrative approach to understanding the role of chemerin in human health and disease Obesity Rev. 2013 14 245 262 10.1111/obr.12009 23216632 
197. Zabel B.A.  Silverio A.M.  Butcher E.C.   Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood J. Immunol. 2005 174 244 251 10.4049/jimmunol.174.1.244 15611246 
198. Zabel B.A.  Nakae S.  Zuniga L.  Kim J.Y.  Ohyama T.  Alt C.  Pan J.  Suto H.  Soler D.  Allen S.J.    Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis J. Exp. Med. 2008 205 2207 2220 10.1084/jem.20080300 18794339 
199. Barnea G.  Strapps W.  Herrada G.  Berman Y.  Ong J.  Kloss B.  Axel R.  Lee K.J.   The genetic design of signaling cascades to record receptor activation Proc. Natl. Acad. Sci. USA 2008 105 64 69 10.1073/pnas.0710487105 18165312 
200. Goralski K.B.  McCarthy T.C.  Hanniman E.A.  Zabel B.A.  Butcher E.C.  Parlee S.D.  Muruganandan S.  Sinal C.J.   Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism J. Biol. Chem. 2007 282 28175 28188 10.1074/jbc.M700793200 17635925 
201. Nagpal S.  Patel S.  Jacobe H.  DiSepio D.  Ghosn C.  Malhotra M.  Teng M.  Duvic M.  Chandraratna R.A.   Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin J. Investig. Dermatol. 1997 109 91 95 10.1111/1523-1747.ep12276660 9204961 
202. Bozaoglu K.  Curran J.E.  Stocker C.J.  Zaibi M.S.  Segal D.  Konstantopoulos N.  Morrison S.  Carless M.  Dyer T.D.  Cole S.A.    Chemerin, a novel adipokine in the regulation of angiogenesis J. Clin. Endocrinol. Metab. 2010 95 2476 2485 10.1210/jc.2010-0042 20237162 
203. Zabel B.A.  Allen S.J.  Kulig P.  Allen J.A.  Cichy J.  Handel T.M.  Butcher E.C.   Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades J. Biol. Chem. 2005 280 34661 34666 10.1074/jbc.M504868200 16096270 
204. Bozaoglu K.  Bolton K.  McMillan J.  Zimmet P.  Jowett J.  Collier G.  Walder K.  Segal D.   Chemerin is a novel adipokine associated with obesity and metabolic syndrome Endocrinology 2007 148 4687 4694 10.1210/en.2007-0175 17640997 
205. Sell H.  Laurencikiene J.  Taube A.  Eckardt K.  Cramer A.  Horrighs A.  Arner P.  Eckel J.   Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells Diabetes 2009 58 2731 2740 10.2337/db09-0277 19720798 
206. Chakaroun R.  Raschpichler M.  Kloting N.  Oberbach A.  Flehmig G.  Kern M.  Schon M.R.  Shang E.  Lohmann T.  Dressler M.    Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity Metabolism 2012 61 706 714 10.1016/j.metabol.2011.10.008 22136911 
207. Wargent E.T.  Zaibi M.S.  O’Dowd J.F.  Cawthorne M.A.  Wang S.J.  Arch J.R.  Stocker C.J.   Evidence from studies in rodents and in isolated adipocytes that agonists of the chemerin receptor CMKLR1 may be beneficial in the treatment of type 2 diabetes PeerJ 2015 3 e753 10.7717/peerj.753 25699203 
208. Ernst M.C.  Issa M.  Goralski K.B.  Sinal C.J.   Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes Endocrinology 2010 151 1998 2007 10.1210/en.2009-1098 20228173 
209. Takahashi M.  Okimura Y.  Iguchi G.  Nishizawa H.  Yamamoto M.  Suda K.  Kitazawa R.  Fujimoto W.  Takahashi K.  Zolotaryov F.N.    Chemerin regulates beta-cell function in mice Sci. Rep. 2011 1 123 10.1038/srep00123 22355640 
210. Ernst M.C.  Haidl I.D.  Zuniga L.A.  Dranse H.J.  Rourke J.L.  Zabel B.A.  Butcher E.C.  Sinal C.J.   Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance Endocrinology 2012 153 672 682 10.1210/en.2011-1490 22186410 
211. Huang C.  Wang M.  Ren L.  Xiang L.  Chen J.  Li M.  Xiao T.  Ren P.  Xiong L.  Zhang J.V.   CMKLR1 deficiency influences glucose tolerance and thermogenesis in mice on high fat diet Biochem. Biophys. Res. Commun. 2016 473 435 441 10.1016/j.bbrc.2016.03.026 26972253 
212. Rourke J.L.  Muruganandan S.  Dranse H.J.  McMullen N.M.  Sinal C.J.   Gpr1 is an active chemerin receptor influencing glucose homeostasis in obese mice J. Endocrinol. 2014 222 201 215 10.1530/JOE-14-0069 24895415 
213. Helfer G.  Ross A.W.  Thomson L.M.  Mayer C.D.  Stoney P.N.  McCaffery P.J.  Morgan P.J.   A neuroendocrine role for chemerin in hypothalamic remodelling and photoperiodic control of energy balance Sci. Rep. 2016 6 26830 10.1038/srep26830 27225311 
214. Perumalsamy S.  Aqilah Mohd Zin N.A.  Widodo R.T.  Wan Ahmad W.A.  Vethakkan S.  Huri H.Z.   Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer Curr. Pharm. Des. 2017 23 3689 3698 10.2174/1381612823666170616081256 28625137 
215. Zhang Y.  Xu N.  Ding Y.  Doycheva D.M.  Zhang Y.  Li Q.  Flores J.  Haghighiabyaneh M.  Tang J.  Zhang J.H.   Chemerin reverses neurological impairments and ameliorates neuronal apoptosis through ChemR23/CAMKK2/AMPK pathway in neonatal hypoxic-ischemic encephalopathy Cell Death Dis. 2019 10 97 10.1038/s41419-019-1374-y 30718467 
216. Peng L.  Yu Y.  Liu J.  Li S.  He H.  Cheng N.  Ye R.D.   The chemerin receptor CMKLR1 is a functional receptor for amyloid-beta peptide J. Alzheimers Dis. 2015 43 227 242 10.3233/JAD-141227 25079809 
217. Guo X.  Fu Y.  Xu Y.  Weng S.  Liu D.  Cui D.  Yu S.  Liu X.  Jiang K.  Dong Y.   Chronic mild restraint stress rats decreased CMKLR1 expression in distinct brain region Neurosci. Lett. 2012 524 25 29 10.1016/j.neulet.2012.06.075 22796467 
218. Deyama S.  Shimoda K.  Suzuki H.  Ishikawa Y.  Ishimura K.  Fukuda H.  Hitora-Imamura N.  Ide S.  Satoh M.  Kaneda K.    Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23 Psychopharmacology 2018 235 329 336 10.1007/s00213-017-4774-7 29090333 
219. Guo L.  Li Q.  Wang W.  Yu P.  Pan H.  Li P.  Sun Y.  Zhang J.   Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B Endocr Res. 2009 34 142 154 10.3109/07435800903287079 19878074 
220. Bertrand C.  Valet P.  Castan-Laurell I.   Apelin and energy metabolism Front. Physiol. 2015 6 115 10.3389/fphys.2015.00115 25914650 
221. Wu L.  Chen L.  Li L.   Apelin/APJ system: A novel promising therapy target for pathological angiogenesis Clin. Chim. Acta 2017 466 78 84 10.1016/j.cca.2016.12.023 28025030 
222. Yamaleyeva L.M.  Shaltout H.A.  Varagic J.   Apelin-13 in blood pressure regulation and cardiovascular disease Curr. Opin. Nephrol. Hypertens. 2016 25 396 403 10.1097/MNH.0000000000000241 27258138 
223. Valle A.  Hoggard N.  Adams A.C.  Roca P.  Speakman J.R.   Chronic central administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL/6 mice J. Neuroendocrinol. 2008 20 79 84 10.1111/j.1365-2826.2007.01617.x 18081555 
224. Vinel C.  Lukjanenko L.  Batut A.  Deleruyelle S.  Pradere J.P.  Le Gonidec S.  Dortignac A.  Geoffre N.  Pereira O.  Karaz S.    The exerkine apelin reverses age-associated sarcopenia Nat. Med. 2018 24 1360 1371 10.1038/s41591-018-0131-6 30061698 
225. Castan-Laurell I.  Dray C.  Knauf C.  Kunduzova O.  Valet P.   Apelin, a promising target for type 2 diabetes treatment? Trends Endocrinol. Metab. 2012 23 234 241 10.1016/j.tem.2012.02.005 22445464 
226. Pope G.R.  Roberts E.M.  Lolait S.J.  O’Carroll A.M.   Central and peripheral apelin receptor distribution in the mouse: Species differences with rat Peptides 2012 33 139 148 10.1016/j.peptides.2011.12.005 22197493 
227. Yue P.  Jin H.  Xu S.  Aillaud M.  Deng A.C.  Azuma J.  Kundu R.K.  Reaven G.M.  Quertermous T.  Tsao P.S.   Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms Endocrinology 2011 152 59 68 10.1210/en.2010-0576 21047945 
228. Yue P.  Jin H.  Aillaud M.  Deng A.C.  Azuma J.  Asagami T.  Kundu R.K.  Reaven G.M.  Quertermous T.  Tsao P.S.   Apelin is necessary for the maintenance of insulin sensitivity Am. J. Physiol. Endocrinol. Metab. 2010 298 E59 E67 10.1152/ajpendo.00385.2009 19861585 
229. Dray C.  Knauf C.  Daviaud D.  Waget A.  Boucher J.  Buleon M.  Cani P.D.  Attane C.  Guigne C.  Carpene C.    Apelin stimulates glucose utilization in normal and obese insulin-resistant mice Cell Metab. 2008 8 437 445 10.1016/j.cmet.2008.10.003 19046574 
230. Attane C.  Foussal C.  Le Gonidec S.  Benani A.  Daviaud D.  Wanecq E.  Guzman-Ruiz R.  Dray C.  Bezaire V.  Rancoule C.    Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice Diabetes 2012 61 310 320 10.2337/db11-0100 22210322 
231. Than A.  Cheng Y.  Foh L.C.  Leow M.K.  Lim S.C.  Chuah Y.J.  Kang Y.  Chen P.   Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways Mol. Cell Endocrinol. 2012 362 227 241 10.1016/j.mce.2012.07.002 22842084 
232. Zhu S.  Sun F.  Li W.  Cao Y.  Wang C.  Wang Y.  Liang D.  Zhang R.  Zhang S.  Wang H.    Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes Mol. Cell Biochem. 2011 353 305 313 10.1007/s11010-011-0799-0 21461612 
233. Cheng B.  Chen J.  Bai B.  Xin Q.   Neuroprotection of apelin and its signaling pathway Peptides 2012 37 171 173 10.1016/j.peptides.2012.07.012 22820556 
234. Xin Q.  Cheng B.  Pan Y.  Liu H.  Yang C.  Chen J.  Bai B.   Neuroprotective effects of apelin-13 on experimental ischemic stroke through suppression of inflammation Peptides 2015 63 55 62 10.1016/j.peptides.2014.09.016 25278489 
235. Chu H.  Yang X.  Huang C.  Gao Z.  Tang Y.  Dong Q.   Apelin-13 Protects against Ischemic Blood-Brain Barrier Damage through the Effects of Aquaporin-4 Cerebrovasc. Dis. 2017 44 10 25 10.1159/000460261 28402976 
236. Chen D.  Lee J.  Gu X.  Wei L.  Yu S.P.   Intranasal Delivery of Apelin-13 Is Neuroprotective and Promotes Angiogenesis After Ischemic Stroke in Mice ASN Neuro 2015 7 10.1177/1759091415605114 26391329 
237. Bao H.J.  Zhang L.  Han W.C.  Dai D.K.   Apelin-13 attenuates traumatic brain injury-induced damage by suppressing autophagy Neurochem. Res. 2015 40 89 97 10.1007/s11064-014-1469-x 25362565 
238. Luo H.  Xiang Y.  Qu X.  Liu H.  Liu C.  Li G.  Han L.  Qin X.   Apelin-13 Suppresses Neuroinflammation Against Cognitive Deficit in a Streptozotocin-Induced Rat Model of Alzheimer’s Disease Through Activation of BDNF-TrkB Signaling Pathway Front. Pharmacol. 2019 10 395 10.3389/fphar.2019.00395 31040784 
239. Li E.  Deng H.  Wang B.  Fu W.  You Y.  Tian S.   Apelin-13 exerts antidepressant-like and recognition memory improving activities in stressed rats Eur. Neuropsychopharmacol. 2016 26 420 430 10.1016/j.euroneuro.2016.01.007 26853763 
240. Xiao Z.Y.  Wang B.  Fu W.  Jin X.  You Y.  Tian S.W.  Kuang X.   The Hippocampus is a Critical Site Mediating Antidepressant-like Activity of Apelin-13 in Rats Neuroscience 2018 375 1 9 10.1016/j.neuroscience.2018.02.001 29432881 
241. Dai T.T.  Wang B.  Xiao Z.Y.  You Y.  Tian S.W.   Apelin-13 Upregulates BDNF Against Chronic Stress-induced Depression-like Phenotypes by Ameliorating HPA Axis and Hippocampal Glucocorticoid Receptor Dysfunctions Neuroscience 2018 390 151 159 10.1016/j.neuroscience.2018.08.018 30170158 
242. Revollo J.R.  Grimm A.A.  Imai S.   The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells J. Biol. Chem. 2004 279 50754 50763 10.1074/jbc.M408388200 15381699 
243. Garten A.  Schuster S.  Penke M.  Gorski T.  de Giorgis T.  Kiess W.   Physiological and pathophysiological roles of NAMPT and NAD metabolism Nat. Rev. Endocrinol. 2015 11 535 546 10.1038/nrendo.2015.117 26215259 
244. Yoshino J.  Mills K.F.  Yoon M.J.  Imai S.   Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice Cell Metab. 2011 14 528 536 10.1016/j.cmet.2011.08.014 21982712 
245. Chalkiadaki A.  Guarente L.   High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction Cell Metab. 2012 16 180 188 10.1016/j.cmet.2012.07.003 22883230 
246. Chen D.  Bruno J.  Easlon E.  Lin S.J.  Cheng H.L.  Alt F.W.  Guarente L.   Tissue-specific regulation of SIRT1 by calorie restriction Genes Dev. 2008 22 1753 1757 10.1101/gad.1650608 18550784 
247. Song J.  Ke S.F.  Zhou C.C.  Zhang S.L.  Guan Y.F.  Xu T.Y.  Sheng C.Q.  Wang P.  Miao C.Y.   Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation J. Gerontol. A Biol. Sci. Med. Sci. 2014 69 44 57 10.1093/gerona/glt122 23946338 
248. Stromsdorfer K.L.  Yamaguchi S.  Yoon M.J.  Moseley A.C.  Franczyk M.P.  Kelly S.C.  Qi N.  Imai S.  Yoshino J.   NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice Cell Rep. 2016 16 1851 1860 10.1016/j.celrep.2016.07.027 27498863 
249. Yoon M.J.  Yoshida M.  Johnson S.  Takikawa A.  Usui I.  Tobe K.  Nakagawa T.  Yoshino J.  Imai S.   SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice Cell Metab. 2015 21 706 717 10.1016/j.cmet.2015.04.002 25921090 
250. Jing Z.  Xing J.  Chen X.  Stetler R.A.  Weng Z.  Gan Y.  Zhang F.  Gao Y.  Chen J.  Leak R.K.    Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury J. Cereb Blood Flow Metab. 2014 34 1613 1621 10.1038/jcbfm.2014.119 25005877 
251. Erfani S.  Khaksari M.  Oryan S.  Shamsaei N.  Aboutaleb N.  Nikbakht F.   Nampt/PBEF/visfatin exerts neuroprotective effects against ischemia/reperfusion injury via modulation of Bax/Bcl-2 ratio and prevention of caspase-3 activation J. Mol. Neurosci. 2015 56 237 243 10.1007/s12031-014-0486-1 25603815 
252. Zhao Y.  Guan Y.F.  Zhou X.M.  Li G.Q.  Li Z.Y.  Zhou C.C.  Wang P.  Miao C.Y.   Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade Stroke 2015 46 1966 1974 10.1161/STROKEAHA.115.009216 26060246 
253. Zhao Y.  Liu X.Z.  Tian W.W.  Guan Y.F.  Wang P.  Miao C.Y.   Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury CNS Neurosci. Ther. 2014 20 539 547 10.1111/cns.12273 24750959 
254. Zhang H.  Ryu D.  Wu Y.  Gariani K.  Wang X.  Luan P.  D’Amico D.  Ropelle E.R.  Lutolf M.P.  Aebersold R.    NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice Science 2016 352 1436 1443 10.1126/science.aaf2693 27127236 
255. Fricker R.A.  Green E.L.  Jenkins S.I.  Griffin S.M.   The Influence of Nicotinamide on Health and Disease in the Central Nervous System Int. J. Tryptophan Res. 2018 11 1178646918776658 10.1177/1178646918776658 29844677 
256. Wang X.  Hu X.  Yang Y.  Takata T.  Sakurai T.   Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death Brain Res. 2016 1643 1 9 10.1016/j.brainres.2016.04.060 27130898 
257. Gong B.  Pan Y.  Vempati P.  Zhao W.  Knable L.  Ho L.  Wang J.  Sastre M.  Ono K.  Sauve A.A.    Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models Neurobiol. Aging 2013 34 1581 1588 10.1016/j.neurobiolaging.2012.12.005 23312803 
258. Cao H.  Gerhold K.  Mayers J.R.  Wiest M.M.  Watkins S.M.  Hotamisligil G.S.   Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism Cell 2008 134 933 944 10.1016/j.cell.2008.07.048 18805087 
259. Saunders A.M.  Strittmatter W.J.  Schmechel D.  George-Hyslop P.H.  Pericak-Vance M.A.  Joo S.H.  Rosi B.L.  Gusella J.F.  Crapper-MacLachlan D.R.  Alberts M.J.    Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease Neurology 1993 43 1467 1472 10.1212/WNL.43.8.1467 8350998 
260. Cutler R.G.  Kelly J.  Storie K.  Pedersen W.A.  Tammara A.  Hatanpaa K.  Troncoso J.C.  Mattson M.P.   Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease Proc. Natl. Acad. Sci. USA 2004 101 2070 2075 10.1073/pnas.0305799101 14970312 
261. Lukiw W.J.  Pappolla M.  Pelaez R.P.  Bazan N.G.   Alzheimer’s disease--a dysfunction in cholesterol and lipid metabolism Cell Mol. Neurobiol. 2005 25 475 483 10.1007/s10571-005-4010-6 16075376 
262. Zhao Y.  Calon F.  Julien C.  Winkler J.W.  Petasis N.A.  Lukiw W.J.  Bazan N.G.   Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer’s disease models PLoS ONE 2011 6 e15816 10.1371/journal.pone.0015816 21246057 
263. Sanchez-Mejia R.O.  Newman J.W.  Toh S.  Yu G.Q.  Zhou Y.  Halabisky B.  Cisse M.  Scearce-Levie K.  Cheng I.H.  Gan L.    Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease Nat. Neurosci. 2008 11 1311 1318 10.1038/nn.2213 18931664 
264. Grimm M.O.  Grimm H.S.  Patzold A.J.  Zinser E.G.  Halonen R.  Duering M.  Tschape J.A.  De Strooper B.  Muller U.  Shen J.    Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin Nat. Cell Biol. 2005 7 1118 1123 10.1038/ncb1313 16227967 
265. Okada T.  Furuhashi N.  Kuromori Y.  Miyashita M.  Iwata F.  Harada K.   Plasma palmitoleic acid content and obesity in children Am. J. Clin. Nutr. 2005 82 747 750 10.1093/ajcn/82.4.747 16210702 
266. Paillard F.  Catheline D.  Duff F.L.  Bouriel M.  Deugnier Y.  Pouchard M.  Daubert J.C.  Legrand P.   Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity Nutr. Metab. Cardiovasc. Dis. 2008 18 436 440 10.1016/j.numecd.2007.02.017 18068341 
267. Warensjo E.  Ohrvall M.  Vessby B.   Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women Nutr. Metab. Cardiovasc. Dis. 2006 16 128 136 10.1016/j.numecd.2005.06.001 16487913 
268. Mozaffarian D.  Cao H.  King I.B.  Lemaitre R.N.  Song X.  Siscovick D.S.  Hotamisligil G.S.   Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes Am. J. Clin. Nutr. 2010 92 1350 1358 10.3945/ajcn.110.003970 20943795 
269. Ferry G.  Tellier E.  Try A.  Gres S.  Naime I.  Simon M.F.  Rodriguez M.  Boucher J.  Tack I.  Gesta S.    Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity J. Biol. Chem. 2003 278 18162 18169 10.1074/jbc.M301158200 12642576 
270. Gesta S.  Simon M.F.  Rey A.  Sibrac D.  Girard A.  Lafontan M.  Valet P.  Saulnier-Blache J.S.   Secretion of a lysophospholipase D activity by adipocytes: Involvement in lysophosphatidic acid synthesis J. Lipid Res. 2002 43 904 910 12032165 
271. Boucher J.  Quilliot D.  Praderes J.P.  Simon M.F.  Gres S.  Guigne C.  Prevot D.  Ferry G.  Boutin J.A.  Carpene C.    Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression Diabetologia 2005 48 569 577 10.1007/s00125-004-1660-8 15700135 
272. Dusaulcy R.  Rancoule C.  Gres S.  Wanecq E.  Colom A.  Guigne C.  van Meeteren L.A.  Moolenaar W.H.  Valet P.  Saulnier-Blache J.S.   Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid J. Lipid Res. 2011 52 1247 1255 10.1194/jlr.M014985 21421848 
273. Rancoule C.  Dusaulcy R.  Treguer K.  Gres S.  Guigne C.  Quilliot D.  Valet P.  Saulnier-Blache J.S.   Depot-specific regulation of autotaxin with obesity in human adipose tissue J. Physiol. Biochem. 2012 68 635 644 10.1007/s13105-012-0181-z 22644624 
274. Rachakonda V.P.  Reeves V.L.  Aljammal J.  Wills R.C.  Trybula J.S.  DeLany J.P.  Kienesberger P.C.  Kershaw E.E.   Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity Obesity (Silver Spring) 2015 23 965 972 10.1002/oby.20960 25865747 
275. Reeves V.L.  Trybula J.S.  Wills R.C.  Goodpaster B.H.  Dube J.J.  Kienesberger P.C.  Kershaw E.E.   Serum Autotaxin/ENPP2 correlates with insulin resistance in older humans with obesity Obesity (Silver Spring) 2015 23 2371 2376 10.1002/oby.21232 26727116 
276. D’Souza K.  Kane D.A.  Touaibia M.  Kershaw E.E.  Pulinilkunnil T.  Kienesberger P.C.   Autotaxin Is Regulated by Glucose and Insulin in Adipocytes Endocrinology 2017 158 791 803 10.1210/en.2017-00035 28324037 
277. Rancoule C.  Attane C.  Gres S.  Fournel A.  Dusaulcy R.  Bertrand C.  Vinel C.  Treguer K.  Prentki M.  Valet P.    Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice Diabetologia 2013 56 1394 1402 10.1007/s00125-013-2891-3 23508306 
278. Yung Y.C.  Stoddard N.C.  Chun J.   LPA receptor signaling: Pharmacology, physiology, and pathophysiology J. Lipid Res. 2014 55 1192 1214 10.1194/jlr.R046458 24643338 
279. Gimenez da Silva-Santi L.  Masetto Antunes M.  Mori M.A.  Biesdorf de Almeida-Souza C.  Vergilio Visentainer J.  Carbonera F.  Rabello Crisma A.  Nunes Masi L.  Massao Hirabara S.  Curi R.    Brain Fatty Acid Composition and Inflammation in Mice Fed with High-Carbohydrate Diet or High-Fat Diet Nutrients 2018 10 10.3390/nu10091277 30201883 
280. Lee J.C.  Park S.M.  Kim I.Y.  Sung H.  Seong J.K.  Moon M.H.   High-fat diet-induced lipidome perturbations in the cortex, hippocampus, hypothalamus, and olfactory bulb of mice Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2018 1863 980 990 10.1016/j.bbalip.2018.05.007 29787912 
281. Agrawal R.  Gomez-Pinilla F.   ‘Metabolic syndrome’ in the brain: Deficiency in omega-3 fatty acid exacerbates dysfunctions in insulin receptor signalling and cognition J. Physiol. 2012 590 2485 2499 10.1113/jphysiol.2012.230078 22473784 
282. Sharma S.  Zhuang Y.  Gomez-Pinilla F.   High-fat diet transition reduces brain DHA levels associated with altered brain plasticity and behaviour Sci. Rep. 2012 2 431 10.1038/srep00431 22666534 
283. Sato N.  Morishita R.   The roles of lipid and glucose metabolism in modulation of beta-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease Front. Aging Neurosci. 2015 7 199 10.3389/fnagi.2015.00199 26557086 
284. Janssen C.I.  Jansen D.  Mutsaers M.P.  Dederen P.J.  Geenen B.  Mulder M.T.  Kiliaan A.J.   The Effect of a High-Fat Diet on Brain Plasticity, Inflammation and Cognition in Female ApoE4-Knockin and ApoE-Knockout Mice PLoS ONE 2016 11 e0155307 10.1371/journal.pone.0155307 27171180 
285. Zhu T.B.  Zhang Z.  Luo P.  Wang S.S.  Peng Y.  Chu S.F.  Chen N.H.   Lipid metabolism in Alzheimer’s disease Brain Res. Bull. 2019 144 68 74 10.1016/j.brainresbull.2018.11.012 30472149 
286. Del Olmo N.  Ruiz-Gayo M.   Influence of High-Fat Diets Consumed During the Juvenile Period on Hippocampal Morphology and Function Front. Cell Neurosci. 2018 12 439 10.3389/fncel.2018.00439 30515083 
287. Carta G.  Murru E.  Banni S.  Manca C.   Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications Front. Physiol. 2017 8 902 10.3389/fphys.2017.00902 29167646 
288. Strable M.S.  Ntambi J.M.   Genetic control of de novo lipogenesis: Role in diet-induced obesity Crit. Rev. Biochem. Mol. Biol. 2010 45 199 214 10.3109/10409231003667500 20218765 
289. Silbernagel G.  Kovarova M.  Cegan A.  Machann J.  Schick F.  Lehmann R.  Haring H.U.  Stefan N.  Schleicher E.  Fritsche A.    High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet J. Clin. Endocrinol. Metab. 2012 97 E2288 E2292 10.1210/jc.2012-2152 23015656 
290. Patil S.  Balu D.  Melrose J.  Chan C.   Brain region-specificity of palmitic acid-induced abnormalities associated with Alzheimer’s disease BMC Res. Notes 2008 1 20 10.1186/1756-0500-1-20 18710535 
291. Hsiao Y.H.  Lin C.I.  Liao H.  Chen Y.H.  Lin S.H.   Palmitic acid-induced neuron cell cycle G2/M arrest and endoplasmic reticular stress through protein palmitoylation in SH-SY5Y human neuroblastoma cells Int. J. Mol. Sci. 2014 15 20876 20899 10.3390/ijms151120876 25402647 
292. Patil S.  Melrose J.  Chan C.   Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons Eur. J. Neurosci. 2007 26 2131 2141 10.1111/j.1460-9568.2007.05797.x 17908174 
293. Frigolet M.E.  Gutierrez-Aguilar R.   The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease Adv. Nutr. 2017 8 173S 181S 10.3945/an.115.011130 28096141 
294. Guo X.  Li H.  Xu H.  Halim V.  Zhang W.  Wang H.  Ong K.T.  Woo S.L.  Walzem R.L.  Mashek D.G.    Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice PLoS ONE 2012 7 e39286 10.1371/journal.pone.0039286 22768070 
295. Ouchi N.  Parker J.L.  Lugus J.J.  Walsh K.   Adipokines in inflammation and metabolic disease Nat. Rev. Immunol. 2011 11 85 97 10.1038/nri2921 21252989 
296. Bolsoni-Lopes A.  Festuccia W.T.  Farias T.S.  Chimin P.  Torres-Leal F.L.  Derogis P.B.  de Andrade P.B.  Miyamoto S.  Lima F.B.  Curi R.    Palmitoleic acid (n-7) increases white adipocyte lipolysis and lipase content in a PPARalpha-dependent manner Am. J. Physiol. Endocrinol. Metab. 2013 305 E1093 E1102 10.1152/ajpendo.00082.2013 24022867 
297. Dimopoulos N.  Watson M.  Sakamoto K.  Hundal H.S.   Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells Biochem. J. 2006 399 473 481 10.1042/BJ20060244 16822230 
298. Kuda O.  Stankova B.  Tvrzicka E.  Hensler M.  Jelenik T.  Rossmeisl M.  Flachs P.  Kopecky J.   Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet J. Physiol. Pharmacol. 2009 60 135 140 20065507 
299. Furuhashi M.  Hotamisligil G.S.   Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets Nat. Rev. Drug Discov. 2008 7 489 503 10.1038/nrd2589 18511927 
300. Furuhashi M.  Ishimura S.  Ota H.  Miura T.   Lipid chaperones and metabolic inflammation Int. J. Inflam. 2011 2011 642612 10.4061/2011/642612 22121495 
301. Tan K.C.  Wat N.M.  Tam S.C.  Janus E.D.  Lam T.H.  Lam K.S.   C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance Diabetes Care 2003 26 2323 2328 10.2337/diacare.26.8.2323 12882856 
302. Liu M.Y.  Xydakis A.M.  Hoogeveen R.C.  Jones P.H.  Smith E.O.  Nelson K.W.  Ballantyne C.M.   Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system Clin. Chem. 2005 51 1102 1109 10.1373/clinchem.2004.047084 15976097 
303. Degawa-Yamauchi M.  Bovenkerk J.E.  Juliar B.E.  Watson W.  Kerr K.  Jones R.  Zhu Q.  Considine R.V.   Serum resistin (FIZZ3) protein is increased in obese humans J. Clin. Endocrinol. Metab. 2003 88 5452 5455 10.1210/jc.2002-021808 14602788 
304. Xu A.  Wang Y.  Xu J.Y.  Stejskal D.  Tam S.  Zhang J.  Wat N.M.  Wong W.K.  Lam K.S.   Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome Clin. Chem. 2006 52 405 413 10.1373/clinchem.2005.062463 16423904 
305. Kralisch S.  Ebert T.  Lossner U.  Jessnitzer B.  Stumvoll M.  Fasshauer M.   Adipocyte fatty acid-binding protein is released from adipocytes by a non-conventional mechanism Int J. Obes. (Lond.) 2014 38 1251 1254 10.1038/ijo.2013.232 24445660 
306. Erbay E.  Babaev V.R.  Mayers J.R.  Makowski L.  Charles K.N.  Snitow M.E.  Fazio S.  Wiest M.M.  Watkins S.M.  Linton M.F.    Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis Nat. Med. 2009 15 1383 1391 10.1038/nm.2067 19966778 
307. Coleman S.L.  Park Y.K.  Lee J.Y.   Unsaturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages Eur. J. Nutr. 2011 50 323 330 10.1007/s00394-010-0140-9 21046125 
308. Uysal K.T.  Scheja L.  Wiesbrock S.M.  Bonner-Weir S.  Hotamisligil G.S.   Improved glucose and lipid metabolism in genetically obese mice lacking aP2 Endocrinology 2000 141 3388 3396 10.1210/endo.141.9.7637 10965911 
309. Maeda K.  Cao H.  Kono K.  Gorgun C.Z.  Furuhashi M.  Uysal K.T.  Cao Q.  Atsumi G.  Malone H.  Krishnan B.    Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes Cell Metab. 2005 1 107 119 10.1016/j.cmet.2004.12.008 16054052 
310. Cao H.  Maeda K.  Gorgun C.Z.  Kim H.J.  Park S.Y.  Shulman G.I.  Kim J.K.  Hotamisligil G.S.   Regulation of metabolic responses by adipocyte/macrophage Fatty Acid-binding proteins in leptin-deficient mice Diabetes 2006 55 1915 1922 10.2337/db05-1496 16804058 
311. Dobrzyn P.  Jazurek M.  Dobrzyn A.   Stearoyl-CoA desaturase and insulin signaling--what is the molecular switch? Biochim. Biophys. Acta 2010 1797 1189 1194 10.1016/j.bbabio.2010.02.007 20153289 
312. Astarita G.  Jung K.M.  Vasilevko V.  Dipatrizio N.V.  Martin S.K.  Cribbs D.H.  Head E.  Cotman C.W.  Piomelli D.   Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease PLoS ONE 2011 6 e24777 10.1371/journal.pone.0024777 22046234 
313. Cohen P.  Miyazaki M.  Socci N.D.  Hagge-Greenberg A.  Liedtke W.  Soukas A.A.  Sharma R.  Hudgins L.C.  Ntambi J.M.  Friedman J.M.   Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss Science 2002 297 240 243 10.1126/science.1071527 12114623 
314. Corpeleijn E.  Feskens E.J.  Jansen E.H.  Mensink M.  Saris W.H.  de Bruin T.W.  Blaak E.E.   Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: The SLIM study Diabetologia 2006 49 2392 2401 10.1007/s00125-006-0383-4 16896932 
315. Warensjo E.  Ingelsson E.  Lundmark P.  Lannfelt L.  Syvanen A.C.  Vessby B.  Riserus U.   Polymorphisms in the SCD1 gene: Associations with body fat distribution and insulin sensitivity Obesity (Silver Spring) 2007 15 1732 1740 10.1038/oby.2007.206 17636091 
316. Warensjo E.  Riserus U.  Vessby B.   Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men Diabetologia 2005 48 1999 2005 10.1007/s00125-005-1897-x 16132958 
317. Mar-Heyming R.  Miyazaki M.  Weissglas-Volkov D.  Kolaitis N.A.  Sadaat N.  Plaisier C.  Pajukanta P.  Cantor R.M.  de Bruin T.W.  Ntambi J.M.    Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia Arterioscler. Thromb. Vasc. Biol. 2008 28 1193 1199 10.1161/ATVBAHA.107.160150 18340007 
318. Snigdha S.  Astarita G.  Piomelli D.  Cotman C.W.   Effects of diet and behavioral enrichment on free fatty acids in the aged canine brain Neuroscience 2012 202 326 333 10.1016/j.neuroscience.2011.12.002 22183056 
319. Srodulski S.  Sharma S.  Bachstetter A.B.  Brelsfoard J.M.  Pascual C.  Xie X.S.  Saatman K.E.  Van Eldik L.J.  Despa F.   Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin Mol. Neurodegener. 2014 9 30 10.1186/1750-1326-9-30 25149184 
320. Miller A.A.  Spencer S.J.   Obesity and neuroinflammation: A pathway to cognitive impairment Brain Behav. Immun. 2014 42 10 21 10.1016/j.bbi.2014.04.001 24727365 
321. Posey K.A.  Clegg D.J.  Printz R.L.  Byun J.  Morton G.J.  Vivekanandan-Giri A.  Pennathur S.  Baskin D.G.  Heinecke J.W.  Woods S.C.    Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet Am. J. Physiol. Endocrinol. Metab. 2009 296 E1003 E1012 10.1152/ajpendo.90377.2008 19116375 
322. Pistell P.J.  Morrison C.D.  Gupta S.  Knight A.G.  Keller J.N.  Ingram D.K.  Bruce-Keller A.J.   Cognitive impairment following high fat diet consumption is associated with brain inflammation J. Neuroimmunol. 2010 219 25 32 10.1016/j.jneuroim.2009.11.010 20004026 
323. Brandon J.A.  Kraemer M.  Vandra J.  Halder S.  Ubele M.  Morris A.J.  Smyth S.S.   Adipose-derived autotaxin regulates inflammation and steatosis associated with diet-induced obesity PLoS ONE 2019 14 e0208099 10.1371/journal.pone.0208099 30730895 
324. Zhao Y.  Natarajan V.   Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling Biochim. Biophys. Acta 2013 1831 86 92 10.1016/j.bbalip.2012.06.014 22809994 
325. Chen Y.  Ramakrishnan D.P.  Ren B.   Regulation of angiogenesis by phospholipid lysophosphatidic acid Front. Biosci. (Landmark Ed.) 2013 18 852 861 23747852 
326. Estivill-Torrus G.  Llebrez-Zayas P.  Matas-Rico E.  Santin L.  Pedraza C.  De Diego I.  Del Arco I.  Fernandez-Llebrez P.  Chun J.  De Fonseca F.R.   Absence of LPA1 signaling results in defective cortical development Cereb. Cortex 2008 18 938 950 10.1093/cercor/bhm132 17656621 
327. Matas-Rico E.  Garcia-Diaz B.  Llebrez-Zayas P.  Lopez-Barroso D.  Santin L.  Pedraza C.  Smith-Fernandez A.  Fernandez-Llebrez P.  Tellez T.  Redondo M.    Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus Mol. Cell Neurosci. 2008 39 342 355 10.1016/j.mcn.2008.07.014 18708146 
328. Dubin A.E.  Herr D.R.  Chun J.   Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis J. Neurosci. 2010 30 7300 7309 10.1523/JNEUROSCI.6151-09.2010 20505096 
329. Fukushima N.  Shano S.  Moriyama R.  Chun J.   Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA1-G(i/o) pathway Neurochem. Int. 2007 50 302 307 10.1016/j.neuint.2006.09.008 17056154 
330. Furuta D.  Yamane M.  Tsujiuchi T.  Moriyama R.  Fukushima N.   Lysophosphatidic acid induces neurite branch formation through LPA3 Mol. Cell Neurosci. 2012 50 21 34 10.1016/j.mcn.2012.03.006 22465231 
331. Pilpel Y.  Segal M.   The role of LPA1 in formation of synapses among cultured hippocampal neurons J. Neurochem. 2006 97 1379 1392 10.1111/j.1471-4159.2006.03825.x 16638019 
332. Goldin M.  Segal M.   Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons Eur. J. Neurosci. 2003 17 2529 2539 10.1046/j.1460-9568.2003.02694.x 12823460 
333. Pilpel Y.  Segal M.   Activation of PKC induces rapid morphological plasticity in dendrites of hippocampal neurons via Rac and Rho-dependent mechanisms Eur. J. Neurosci. 2004 19 3151 3164 10.1111/j.0953-816X.2004.03380.x 15217371 
334. Harrison S.M.  Reavill C.  Brown G.  Brown J.T.  Cluderay J.E.  Crook B.  Davies C.H.  Dawson L.A.  Grau E.  Heidbreder C.    LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease Mol. Cell Neurosci. 2003 24 1170 1179 10.1016/j.mcn.2003.09.001 14697676 
335. Roberts C.  Winter P.  Shilliam C.S.  Hughes Z.A.  Langmead C.  Maycox P.R.  Dawson L.A.   Neurochemical changes in LPA1 receptor deficient mice--a putative model of schizophrenia Neurochem. Res. 2005 30 371 377 10.1007/s11064-005-2611-6 16018581 
336. Castilla-Ortega E.  Sanchez-Lopez J.  Hoyo-Becerra C.  Matas-Rico E.  Zambrana-Infantes E.  Chun J.  De Fonseca F.R.  Pedraza C.  Estivill-Torrus G.  Santin L.J.   Exploratory, anxiety and spatial memory impairments are dissociated in mice lacking the LPA1 receptor Neurobiol. Learn. Mem. 2010 94 73 82 10.1016/j.nlm.2010.04.003 20388543 
337. Santin L.J.  Bilbao A.  Pedraza C.  Matas-Rico E.  Lopez-Barroso D.  Castilla-Ortega E.  Sanchez-Lopez J.  Riquelme R.  Varela-Nieto I.  de la Villa P.    Behavioral phenotype of maLPA1-null mice: Increased anxiety-like behavior and spatial memory deficits Genes Brain Behav. 2009 8 772 784 10.1111/j.1601-183X.2009.00524.x 19689455 
338. Shano S.  Moriyama R.  Chun J.  Fukushima N.   Lysophosphatidic acid stimulates astrocyte proliferation through LPA1 Neurochem. Int. 2008 52 216 220 10.1016/j.neuint.2007.07.004 17692995 
339. TC E.S.  Dezonne R.S.  Rehen S.K.  Gomes F.C.   Astrocytes treated by lysophosphatidic acid induce axonal outgrowth of cortical progenitors through extracellular matrix protein and epidermal growth factor signaling pathway J. Neurochem. 2011 119 113 123 10.1111/j.1471-4159.2011.07421.x 21834854 
340. Schilling T.  Repp H.  Richter H.  Koschinski A.  Heinemann U.  Dreyer F.  Eder C.   Lysophospholipids induce membrane hyperpolarization in microglia by activation of IKCa1 Ca(2+)-dependent K(+) channels Neuroscience 2002 109 827 835 10.1016/S0306-4522(01)00534-6 11927165 
341. Schilling T.  Stock C.  Schwab A.  Eder C.   Functional importance of Ca2+-activated K+ channels for lysophosphatidic acid-induced microglial migration Eur. J. Neurosci. 2004 19 1469 1474 10.1111/j.1460-9568.2004.03265.x 15066143 
342. Awada R.  Rondeau P.  Gres S.  Saulnier-Blache J.S.  Lefebvre d’Hellencourt C.  Bourdon E.   Autotaxin protects microglial cells against oxidative stress Free Radic. Biol. Med. 2012 52 516 526 10.1016/j.freeradbiomed.2011.11.014 22155714 
343. Awada R.  Saulnier-Blache J.S.  Gres S.  Bourdon E.  Rondeau P.  Parimisetty A.  Orihuela R.  Harry G.J.  d’Hellencourt C.L.   Autotaxin downregulates LPS-induced microglia activation and pro-inflammatory cytokines production J. Cell Biochem. 2014 115 2123 2132 10.1002/jcb.24889 25053164 
344. Moller T.  Musante D.B.  Ransom B.R.   Lysophosphatidic acid-induced calcium signals in cultured rat oligodendrocytes Neuroreport 1999 10 2929 2932 10.1097/00001756-199909290-00010 10549799 
345. Nogaroli L.  Yuelling L.M.  Dennis J.  Gorse K.  Payne S.G.  Fuss B.   Lysophosphatidic acid can support the formation of membranous structures and an increase in MBP mRNA levels in differentiating oligodendrocytes Neurochem. Res. 2009 34 182 193 10.1007/s11064-008-9772-z 18594965 
346. Castanon N.  Luheshi G.  Laye S.   Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity Front. Neurosci. 2015 9 229 10.3389/fnins.2015.00229 26190966 
347. McLimans K.E.  Willette A.A.  Alzheimer’s Disease Neuroimaging I.   Autotaxin is Related to Metabolic Dysfunction and Predicts Alzheimer’s Disease Outcomes J. Alzheimers Dis. 2017 56 403 413 10.3233/JAD-160891 27911319 
348. Shi J.  Dong Y.  Cui M.Z.  Xu X.   Lysophosphatidic acid induces increased BACE1 expression and Abeta formation Biochim. Biophys. Acta 2013 1832 29 38 10.1016/j.bbadis.2012.09.010 23036978 
349. Kinouchi T.  Sorimachi H.  Maruyama K.  Mizuno K.  Ohno S.  Ishiura S.  Suzuki K.   Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer’s disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts FEBS Lett. 1995 364 203 206 7750571 
350. Jolly-Tornetta C.  Wolf B.A.   Regulation of amyloid precursor protein (APP) secretion by protein kinase calpha in human ntera 2 neurons (NT2N) Biochemistry 2000 39 7428 7435 10.1021/bi0003846 10858291 
351. Rossner S.  Mendla K.  Schliebs R.  Bigl V.   Protein kinase Calpha and beta1 isoforms are regulators of alpha-secretory proteolytic processing of amyloid precursor protein in vivo Eur J. Neurosci. 2001 13 1644 1648 10.1046/j.0953-816x.2001.01525.x 11328358 
352. Zhu G.  Wang D.  Lin Y.H.  McMahon T.  Koo E.H.  Messing R.O.   Protein kinase C epsilon suppresses Abeta production and promotes activation of alpha-secretase Biochem. Biophys. Res. Commun. 2001 285 997 1006 10.1006/bbrc.2001.5273 11467851 
353. Blois J.T.  Mataraza J.M.  Mecklenbrauker I.  Tarakhovsky A.  Chiles T.C.   B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase Cdelta J. Biol. Chem. 2004 279 30123 30132 10.1074/jbc.M402793200 15138267 
354. Sayas C.L.  Moreno-Flores M.T.  Avila J.  Wandosell F.   The neurite retraction induced by lysophosphatidic acid increases Alzheimer’s disease-like Tau phosphorylation J. Biol. Chem. 1999 274 37046 37052 10.1074/jbc.274.52.37046 10601262 
355. Sayas C.L.  Avila J.  Wandosell F.   Regulation of neuronal cytoskeleton by lysophosphatidic acid: Role of GSK-3 Biochim. Biophys. Acta 2002 1582 144 153 10.1016/S1388-1981(02)00149-X 12069822 
356. Stranahan A.M.   Models and mechanisms for hippocampal dysfunction in obesity and diabetes Neuroscience 2015 309 125 139 10.1016/j.neuroscience.2015.04.045 25934036 
357. Li X.  Li X.  Lin H.  Fu X.  Lin W.  Li M.  Zeng X.  Gao Q.   Metabolic syndrome and stroke: A meta-analysis of prospective cohort studies J. Clin. Neurosci. 2017 40 34 38 10.1016/j.jocn.2017.01.018 28268148 
358. Butterfield D.A.  Halliwell B.   Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease Nat. Rev. Neurosci. 2019 20 148 160 10.1038/s41583-019-0132-6 30737462 
359. Pousti F.  Ahmadi R.  Mirahmadi F.  Hosseinmardi N.  Rohampour K.   Adiponectin modulates synaptic plasticity in hippocampal dentate gyrus Neurosci. Lett. 2018 662 227 232 10.1016/j.neulet.2017.10.042 29079430 
360. Forny-Germano L.  De Felice F.G.  Vieira M.   The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer’s Disease Front. Neurosci. 2018 12 1027 10.3389/fnins.2018.01027 30692905 
361. Irving A.J.  Harvey J.   Leptin regulation of hippocampal synaptic function in health and disease Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014 369 20130155 10.1098/rstb.2013.0155 24298156 
362. Sun L.N.  Liu X.L.   Functions of adiponectin signaling in regulating neural plasticity and its application as the therapeutic target to neurological and psychiatric diseases Rev. Neurosci. 2019 30 485 495 10.1515/revneuro-2018-0062 30864396 
363. Ghavami S.  Shojaei S.  Yeganeh B.  Ande S.R.  Jangamreddy J.R.  Mehrpour M.  Christoffersson J.  Chaabane W.  Moghadam A.R.  Kashani H.H.    Autophagy and apoptosis dysfunction in neurodegenerative disorders Prog. Neurobiol. 2014 112 24 49 10.1016/j.pneurobio.2013.10.004 24211851 
364. Stephenson J.  Nutma E.  van der Valk P.  Amor S.   Inflammation in CNS neurodegenerative diseases Immunology 2018 154 204 219 10.1111/imm.12922 29513402 
365. Radak D.  Katsiki N.  Resanovic I.  Jovanovic A.  Sudar-Milovanovic E.  Zafirovic S.  Mousad S.A.  Isenovic E.R.   Apoptosis and Acute Brain Ischemia in Ischemic Stroke Curr. Vasc. Pharmacol. 2017 15 115 122 10.2174/1570161115666161104095522 27823556 
366. Jayaraj R.L.  Azimullah S.  Beiram R.  Jalal F.Y.  Rosenberg G.A.   Neuroinflammation: Friend and foe for ischemic stroke J. Neuroinflamm. 2019 16 142 10.1186/s12974-019-1516-2 31291966 
367. Parimisetty A.  Dorsemans A.C.  Awada R.  Ravanan P.  Diotel N.  Lefebvre d’Hellencourt C.   Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research J. Neuroinflamm. 2016 13 67 10.1186/s12974-016-0530-x 27012931

